Genetic	O	O
mapping	O	O
of	O	O
the	O	O
copper	B-Disease	OMIM:215600
toxicosis	I-Disease	OMIM:215600
locus	O	O
in	O	O
Bedlington	O	O
terriers	O	O
to	O	O
dog	O	O
chromosome	O	O
10	O	O
,	O	O
in	O	O
a	O	O
region	O	O
syntenic	O	O
to	O	O
human	O	O
chromosome	O	O
region	O	O
2p13	O	O
-	O	O
p16	O	O
.	O	O

Mutations	O	O
in	O	O
the	O	O
ATP7B	O	O
genes	O	O
have	O	O
also	O	O
been	O	O
demonstrated	O	O
in	O	O
mouse	O	O
and	O	O
rat	O	O
.	O	O

C04107	O	O
is	O	O
an	O	O
anonymous	O	O
microsatellite	O	O
marker	O	O
closely	O	O
linked	O	O
to	O	O
CT	B-Disease	OMIM:215600
.	O	O

The	O	O
copper	O	O
transport	O	O
genes	O	O
CTR1	O	O
and	O	O
CTR2	O	O
were	O	O
also	O	O
excluded	O	O
as	O	O
candidate	O	O
genes	O	O
for	O	O
CT	B-Disease	OMIM:215600
since	O	O
they	O	O
both	O	O
mapped	O	O
to	O	O
canine	O	O
chromosome	O	O
region	O	O
CFA11q22	O	O
.	O	O

2	O	O
-	O	O
22	O	O
.	O	O

5	O	O
.	O	O

A	O	O
transcribed	O	O
sequence	O	O
identified	O	O
from	O	O
the	O	O
C04107	O	O
-	O	O
containing	O	O
BAC	O	O
was	O	O
found	O	O
to	O	O
be	O	O
homologous	O	O
to	O	O
a	O	O
gene	O	O
expressed	O	O
from	O	O
human	O	O
chromosome	O	O
2p13	O	O
-	O	O
p16	O	O
,	O	O
a	O	O
region	O	O
devoid	O	O
of	O	O
any	O	O
positional	O	O
candidate	O	O
genes	O	O
.	O	O

CONCLUSIONS	O	O
Extended	O	O
genotype	O	O
-	O	O
phenotype	O	O
correlations	O	O
made	O	O
in	O	O
this	O	O
study	O	O
may	O	O
have	O	O
the	O	O
potential	O	O
to	O	O
determine	O	O
the	O	O
most	O	O
appropriate	O	O
surveillance	O	O
and	O	O
prophylactic	O	O
treatment	O	O
regimens	O	O
for	O	O
those	O	O
patients	O	O
with	O	O
mutations	O	O
associated	O	O
with	O	O
life	O	O
threatening	O	O
conditions	O	O
.	O	O

.	O	O

We	O	O
identified	O	O
both	O	O
causative	O	O
mutations	O	O
in	O	O
686	O	O
patients	O	O
from	O	O
seven	O	O
European	O	O
centers	O	O
.	O	O

On	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
phenotypic	O	O
characteristics	O	O
of	O	O
297	O	O
functionally	O	O
hemizygous	O	O
patients	O	O
,	O	O
105	O	O
of	O	O
the	O	O
mutations	O	O
were	O	O
assigned	O	O
to	O	O
one	O	O
of	O	O
four	O	O
arbitrary	O	O
phenotype	O	O
categories	O	O
.	O	O

We	O	O
proposed	O	O
and	O	O
tested	O	O
a	O	O
simple	O	O
model	O	O
for	O	O
correlation	O	O
between	O	O
genotype	O	O
and	O	O
phenotypic	O	O
outcome	O	O
.	O	O

The	O	O
observed	O	O
phenotype	O	O
matched	O	O
the	O	O
predicted	O	O
phenotype	O	O
in	O	O
79	O	O
%	O	O
of	O	O
the	O	O
cases	O	O
,	O	O
and	O	O
in	O	O
only	O	O
5	O	O
of	O	O
184	O	O
patients	O	O
was	O	O
the	O	O
observed	O	O
phenotype	O	O
more	O	O
than	O	O
one	O	O
category	O	O
away	O	O
from	O	O
that	O	O
expected	O	O
.	O	O

Among	O	O
the	O	O
seven	O	O
contributing	O	O
centers	O	O
,	O	O
the	O	O
proportion	O	O
of	O	O
patients	O	O
for	O	O
whom	O	O
the	O	O
observed	O	O
phenotype	O	O
did	O	O
not	O	O
match	O	O
the	O	O
predicted	O	O
phenotype	O	O
was	O	O
4	O	O
%	O	O
-	O	O
23	O	O
%	O	O
(	O	O
P	O	O
<	O	O
.	O	O

0001	O	O
)	O	O
,	O	O
suggesting	O	O
that	O	O
differences	O	O
in	O	O
methods	O	O
used	O	O
for	O	O
mutation	O	O
detection	O	O
or	O	O
phenotype	O	O
classification	O	O
may	O	O
account	O	O
for	O	O
a	O	O
considerable	O	O
proportion	O	O
of	O	O
genotype	O	O
-	O	O
phenotype	O	O
inconsistencies	O	O
.	O	O

Data	O	O
presented	O	O
here	O	O
indicate	O	O
that	O	O
the	O	O
conserved	O	O
heterogeneous	O	O
nuclear	O	O
ribonucleoprotein	O	O
,	O	O
CUG	O	O
-	O	O
binding	O	O
protein	O	O
(	O	O
CUG	O	O
-	O	O
BP	O	O
)	O	O
,	O	O
may	O	O
mediate	O	O
the	O	O
trans	O	O
-	O	O
dominant	O	O
effect	O	O
of	O	O
the	O	O
RNA	O	O
.	O	O

CUG	O	O
-	O	O
BP	O	O
was	O	O
found	O	O
to	O	O
bind	O	O
to	O	O
the	O	O
human	O	O
cardiac	O	O
troponin	O	O
T	O	O
(	O	O
cTNT	O	O
)	O	O
pre	O	O
-	O	O
messenger	O	O
RNA	O	O
and	O	O
regulate	O	O
its	O	O
alternative	O	O
splicing	O	O
.	O	O

.	O	O

2	O	O
)	O	O
.	O	O

2	O	O
)	O	O
with	O	O
simultaneous	O	O
maternal	O	O
meiotic	O	O
nondisjunction	O	O
for	O	O
chromosome	O	O
15	O	O
.	O	O

The	O	O
patient	O	O
(	O	O
J	O	O
.	O	O

B	O	O
.	O	O

The	O	O
t	O	O
(	O	O
3	O	O
;	O	O
15	O	O
)	O	O
was	O	O
present	O	O
in	O	O
the	O	O
balanced	O	O
state	O	O
in	O	O
the	O	O
patients	O	O
father	O	O
and	O	O
a	O	O
sister	O	O
.	O	O

B	O	O
.	O	O

Methylation	O	O
analysis	O	O
at	O	O
exon	O	O
alpha	O	O
of	O	O
the	O	O
small	O	O
nuclear	O	O
ribonucleoprotein	O	O
-	O	O
associated	O	O
polypeptide	O	O
N	O	O
(	O	O
SNRPN	O	O
)	O	O
gene	O	O
showed	O	O
a	O	O
pattern	O	O
characteristic	O	O
of	O	O
only	O	O
the	O	O
maternal	O	O
chromosome	O	O
15	O	O
in	O	O
J	O	O
.	O	O

B	O	O
.	O	O

A	O	O
niece	O	O
(	O	O
B	O	O
.	O	O

B	O	O
.	O	O

)	O	O
with	O	O
45	O	O
chromosomes	O	O
and	O	O
the	O	O
derivative	O	O
3	O	O
but	O	O
without	O	O
the	O	O
der	O	O
(	O	O
15	O	O
)	O	O
demonstrated	O	O
a	O	O
phenotype	O	O
consistent	O	O
with	O	O
that	O	O
reported	O	O
for	O	O
haploinsufficiency	O	O
of	O	O
distal	O	O
3	O	O
p	O	O
.	O	O

Where	O	O
the	O	O
transmitting	O	O
parent	O	O
was	O	O
male	O	O
,	O	O
58	O	O
.	O	O

3	O	O
%	O	O
of	O	O
the	O	O
offspring	O	O
were	O	O
affected	O	O
,	O	O
and	O	O
in	O	O
the	O	O
case	O	O
of	O	O
a	O	O
female	O	O
transmitting	O	O
parent	O	O
,	O	O
68	O	O
.	O	O

7	O	O
%	O	O
were	O	O
affected	O	O
.	O	O

Both	O	O
genomic	O	O
mutations	O	O
and	O	O
their	O	O
effects	O	O
on	O	O
cDNA	O	O
were	O	O
characterized	O	O
.	O	O

Protein	O	O
-	O	O
truncation	O	O
testing	O	O
of	O	O
the	O	O
entire	O	O
ATM	O	O
cDNA	O	O
detected	O	O
92	O	O
(	O	O
66	O	O
%	O	O
)	O	O
truncating	O	O
mutations	O	O
in	O	O
140	O	O
mutant	O	O
alleles	O	O
screened	O	O
.	O	O

The	O	O
haplotyping	O	O
of	O	O
patients	O	O
with	O	O
identical	O	O
mutations	O	O
indicates	O	O
that	O	O
almost	O	O
all	O	O
of	O	O
these	O	O
represent	O	O
common	O	O
ancestry	O	O
and	O	O
that	O	O
very	O	O
few	O	O
spontaneously	O	O
recurring	O	O
ATM	O	O
mutations	O	O
exist	O	O
.	O	O

Assays	O	O
requiring	O	O
minimal	O	O
amounts	O	O
of	O	O
genomic	O	O
DNA	O	O
were	O	O
designed	O	O
to	O	O
allow	O	O
rapid	O	O
screening	O	O
for	O	O
common	O	O
ethnic	O	O
mutations	O	O
.	O	O

These	O	O
rapid	O	O
assays	O	O
detected	O	O
mutations	O	O
in	O	O
76	O	O
%	O	O
of	O	O
Costa	O	O
Rican	O	O
patients	O	O
(	O	O
3	O	O
)	O	O
,	O	O
50	O	O
%	O	O
of	O	O
Norwegian	O	O
patients	O	O
(	O	O
1	O	O
)	O	O
,	O	O
25	O	O
%	O	O
of	O	O
Polish	O	O
patients	O	O
(	O	O
4	O	O
)	O	O
,	O	O
and	O	O
14	O	O
%	O	O
of	O	O
Italian	O	O
patients	O	O
(	O	O
1	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
in	O	O
patients	O	O
of	O	O
Amish	O	O
/	O	O
Mennonite	O	O
and	O	O
Irish	O	O
English	O	O
backgrounds	O	O
.	O	O

Additional	O	O
mutations	O	O
were	O	O
observed	O	O
in	O	O
Japanese	O	O
,	O	O
Utah	O	O
Mormon	O	O
,	O	O
and	O	O
African	O	O
American	O	O
patients	O	O
.	O	O

.	O	O

Three	O	O
of	O	O
13	O	O
uninformative	O	O
patients	O	O
had	O	O
constitutional	O	O
deletions	O	O
.	O	O

In	O	O
6	O	O
(	O	O
17	O	O
%	O	O
)	O	O
of	O	O
the	O	O
36	O	O
patients	O	O
,	O	O
a	O	O
mutation	O	O
was	O	O
detected	O	O
in	O	O
constitutional	O	O
DNA	O	O
,	O	O
and	O	O
1	O	O
of	O	O
these	O	O
mutations	O	O
is	O	O
known	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
reduced	O	O
expressivity	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
a	O	O
constitutional	O	O
mutation	O	O
was	O	O
not	O	O
associated	O	O
with	O	O
an	O	O
early	O	O
age	O	O
at	O	O
treatment	O	O
.	O	O

In	O	O
1	O	O
patient	O	O
,	O	O
somatic	O	O
mosaicism	O	O
was	O	O
demonstrated	O	O
by	O	O
molecular	O	O
analysis	O	O
of	O	O
DNA	O	O
and	O	O
RNA	O	O
from	O	O
peripheral	O	O
blood	O	O
.	O	O

.	O	O

Strikingly	O	O
,	O	O
all	O	O
four	O	O
mutations	O	O
are	O	O
located	O	O
within	O	O
the	O	O
PAX6	O	O
paired	O	O
domain	O	O
and	O	O
affect	O	O
amino	O	O
acids	O	O
which	O	O
are	O	O
highly	O	O
conserved	O	O
in	O	O
all	O	O
known	O	O
paired	O	O
domain	O	O
proteins	O	O
.	O	O

.	O	O

Major	O	O
instability	O	O
,	O	O
with	O	O
very	O	O
large	O	O
expansions	O	O
between	O	O
generations	O	O
and	O	O
high	O	O
levels	O	O
of	O	O
somatic	O	O
mosaicism	O	O
,	O	O
is	O	O
observed	O	O
in	O	O
patients	O	O
.	O	O

There	O	O
is	O	O
a	O	O
good	O	O
correlation	O	O
between	O	O
repeat	O	O
size	O	O
(	O	O
at	O	O
least	O	O
in	O	O
leucocytes	O	O
)	O	O
,	O	O
clinical	O	O
severity	O	O
and	O	O
age	O	O
of	O	O
onset	O	O
.	O	O

These	O	O
mice	O	O
have	O	O
been	O	O
shown	O	O
to	O	O
reproduce	O	O
the	O	O
intergenerational	O	O
and	O	O
somatic	O	O
instability	O	O
of	O	O
the	O	O
55	O	O
CTG	O	O
repeat	O	O
suggesting	O	O
that	O	O
surrounding	O	O
sequences	O	O
and	O	O
the	O	O
chromatin	O	O
environment	O	O
are	O	O
involved	O	O
in	O	O
instability	O	O
mechanisms	O	O
.	O	O

Furthermore	O	O
,	O	O
we	O	O
observed	O	O
no	O	O
correlation	O	O
between	O	O
the	O	O
somatic	O	O
mutation	O	O
rate	O	O
and	O	O
tissue	O	O
proliferation	O	O
capacity	O	O
.	O	O

The	O	O
somatic	O	O
mutation	O	O
rates	O	O
in	O	O
different	O	O
tissues	O	O
were	O	O
also	O	O
not	O	O
correlated	O	O
to	O	O
the	O	O
relative	O	O
inter	O	O
-	O	O
tissue	O	O
difference	O	O
in	O	O
transcriptional	O	O
levels	O	O
of	O	O
the	O	O
three	O	O
genes	O	O
(	O	O
DMAHP	O	O
,	O	O
DMPK	O	O
and	O	O
59	O	O
)	O	O
surrounding	O	O
the	O	O
repeat	O	O
.	O	O

.	O	O

7	O	O
;	O	O
P	O	O
=	O	O
.	O	O

This	O	O
mutation	O	O
(	O	O
7271T	O	O
-	O	O
-	O	O
>	O	O
G	O	O
)	O	O
also	O	O
allows	O	O
expression	O	O
of	O	O
full	O	O
-	O	O
length	O	O
ATM	O	O
protein	O	O
at	O	O
a	O	O
level	O	O
comparable	O	O
with	O	O
that	O	O
in	O	O
unaffected	O	O
individuals	O	O
.	O	O

A	O	O
wide	O	O
variety	O	O
of	O	O
ATM	O	O
mutation	O	O
types	O	O
,	O	O
including	O	O
missense	O	O
mutations	O	O
and	O	O
in	O	O
-	O	O
frame	O	O
deletions	O	O
,	O	O
were	O	O
seen	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

among	O	O
these	O	O
were	O	O
one	O	O
frameshift	O	O
mutation	O	O
,	O	O
one	O	O
nonsense	O	O
mutation	O	O
,	O	O
one	O	O
novel	O	O
splice	O	O
site	O	O
mutation	O	O
,	O	O
and	O	O
one	O	O
missense	O	O
mutation	O	O
.	O	O

The	O	O
missense	O	O
mutation	O	O
was	O	O
also	O	O
found	O	O
in	O	O
2	O	O
.	O	O

8	O	O
%	O	O
of	O	O
the	O	O
general	O	O
population	O	O
,	O	O
suggesting	O	O
that	O	O
it	O	O
is	O	O
not	O	O
disease	O	O
associated	O	O
.	O	O

The	O	O
average	O	O
age	O	O
of	O	O
disease	O	O
onset	O	O
in	O	O
those	O	O
families	O	O
harbouring	O	O
causative	O	O
mutations	O	O
was	O	O
between	O	O
32	O	O
.	O	O

3	O	O
and	O	O
37	O	O
.	O	O

4	O	O
years	O	O
,	O	O
whereas	O	O
the	O	O
family	O	O
harbouring	O	O
the	O	O
missense	O	O
mutation	O	O
had	O	O
an	O	O
average	O	O
age	O	O
of	O	O
onset	O	O
of	O	O
51	O	O
.	O	O

2	O	O
years	O	O
.	O	O

All	O	O
the	O	O
patients	O	O
carried	O	O
a	O	O
pathogenic	O	O
mutation	O	O
in	O	O
either	O	O
BRCA1	O	O
(	O	O
179	O	O
women	O	O
)	O	O
or	O	O
BRCA2	O	O
(	O	O
28	O	O
women	O	O
)	O	O
.	O	O

The	O	O
control	O	O
women	O	O
were	O	O
enrolled	O	O
regardless	O	O
of	O	O
whether	O	O
or	O	O
not	O	O
they	O	O
had	O	O
either	O	O
mutation	O	O
.	O	O

Lifetime	O	O
histories	O	O
of	O	O
oral	O	O
-	O	O
contraceptive	O	O
use	O	O
were	O	O
obtained	O	O
by	O	O
interview	O	O
or	O	O
by	O	O
written	O	O
questionnaire	O	O
and	O	O
were	O	O
compared	O	O
between	O	O
patients	O	O
and	O	O
control	O	O
women	O	O
,	O	O
after	O	O
adjustment	O	O
for	O	O
year	O	O
of	O	O
birth	O	O
and	O	O
parity	O	O
.	O	O

5	O	O
(	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
.	O	O

3	O	O
to	O	O
0	O	O
.	O	O

8	O	O
)	O	O
.	O	O

The	O	O
risk	O	O
decreased	O	O
with	O	O
increasing	O	O
duration	O	O
of	O	O
use	O	O
(	O	O
P	O	O
for	O	O
trend	O	O
,	O	O
<	O	O
0	O	O
.	O	O

001	O	O
)	O	O
;	O	O
use	O	O
for	O	O
six	O	O
or	O	O
more	O	O
years	O	O
was	O	O
associated	O	O
with	O	O
a	O	O
60	O	O
percent	O	O
reduction	O	O
in	O	O
risk	O	O
.	O	O

5	O	O
;	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
.	O	O

3	O	O
to	O	O
0	O	O
.	O	O

9	O	O
)	O	O
and	O	O
for	O	O
carriers	O	O
of	O	O
the	O	O
BRCA2	O	O
mutation	O	O
(	O	O
odds	O	O
ratio	O	O
,	O	O
0	O	O
.	O	O

4	O	O
;	O	O
95	O	O
percent	O	O
confidence	O	O
interval	O	O
,	O	O
0	O	O
.	O	O

2	O	O
to	O	O
1	O	O
.	O	O

1	O	O
)	O	O
.	O	O

Mutations	O	O
were	O	O
found	O	O
in	O	O
41	O	O
of	O	O
97	O	O
families	O	O
.	O	O

Six	O	O
of	O	O
eight	O	O
mutations	O	O
were	O	O
observed	O	O
at	O	O
least	O	O
twice	O	O
.	O	O

The	O	O
BRCA1	O	O
C4446T	O	O
mutation	O	O
was	O	O
the	O	O
most	O	O
common	O	O
mutation	O	O
found	O	O
,	O	O
followed	O	O
by	O	O
the	O	O
BRCA2	O	O
8765delAG	O	O
mutation	O	O
.	O	O

Together	O	O
,	O	O
these	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
28	O	O
of	O	O
41	O	O
families	O	O
identified	O	O
to	O	O
have	O	O
a	O	O
mutation	O	O
.	O	O

The	O	O
odds	O	O
of	O	O
detection	O	O
of	O	O
any	O	O
of	O	O
the	O	O
four	O	O
BRCA1	O	O
mutations	O	O
was	O	O
18	O	O
.	O	O

The	O	O
odds	O	O
of	O	O
detection	O	O
of	O	O
any	O	O
of	O	O
the	O	O
four	O	O
BRCA2	O	O
mutations	O	O
was	O	O
5	O	O
.	O	O

Carriers	O	O
of	O	O
the	O	O
same	O	O
mutation	O	O
,	O	O
from	O	O
different	O	O
families	O	O
,	O	O
shared	O	O
similar	O	O
haplotypes	O	O
,	O	O
indicating	O	O
that	O	O
the	O	O
mutant	O	O
alleles	O	O
were	O	O
likely	O	O
to	O	O
be	O	O
identical	O	O
by	O	O
descent	O	O
for	O	O
a	O	O
mutation	O	O
in	O	O
the	O	O
founder	O	O
population	O	O
.	O	O

Truncation	O	O
mutations	O	O
in	O	O
the	O	O
transactivation	O	O
region	O	O
of	O	O
PAX6	O	O
result	O	O
in	O	O
dominant	O	O
-	O	O
negative	O	O
mutants	O	O
.	O	O

PAX6	O	O
is	O	O
a	O	O
transcription	O	O
factor	O	O
with	O	O
two	O	O
DNA	O	O
-	O	O
binding	O	O
domains	O	O
(	O	O
paired	O	O
box	O	O
and	O	O
homeobox	O	O
)	O	O
and	O	O
a	O	O
proline	O	O
-	O	O
serine	O	O
-	O	O
threonine	O	O
(	O	O
PST	O	O
)	O	O
-	O	O
rich	O	O
transactivation	O	O
domain	O	O
.	O	O

PAX6	O	O
regulates	O	O
eye	O	O
development	O	O
in	O	O
animals	O	O
ranging	O	O
from	O	O
jellyfish	O	O
to	O	O
Drosophila	O	O
to	O	O
humans	O	O
.	O	O

It	O	O
is	O	O
not	O	O
clear	O	O
whether	O	O
such	O	O
mutants	O	O
really	O	O
behave	O	O
as	O	O
loss	O	O
-	O	O
of	O	O
-	O	O
function	O	O
mutants	O	O
as	O	O
predicted	O	O
by	O	O
haploinsufficiency	O	O
.	O	O

Contrary	O	O
to	O	O
this	O	O
theory	O	O
,	O	O
our	O	O
data	O	O
showed	O	O
that	O	O
these	O	O
mutants	O	O
are	O	O
dominant	O	O
-	O	O
negative	O	O
in	O	O
transient	O	O
transfection	O	O
assays	O	O
when	O	O
they	O	O
are	O	O
coexpressed	O	O
with	O	O
wild	O	O
-	O	O
type	O	O
PAX6	O	O
.	O	O

We	O	O
found	O	O
that	O	O
the	O	O
dominant	O	O
-	O	O
negative	O	O
effects	O	O
result	O	O
from	O	O
the	O	O
enhanced	O	O
DNA	O	O
binding	O	O
ability	O	O
of	O	O
these	O	O
mutants	O	O
.	O	O

Kinetic	O	O
studies	O	O
of	O	O
binding	O	O
and	O	O
dissociation	O	O
revealed	O	O
that	O	O
various	O	O
truncation	O	O
mutants	O	O
have	O	O
3	O	O
-	O	O
5	O	O
-	O	O
fold	O	O
higher	O	O
affinity	O	O
to	O	O
various	O	O
DNA	O	O
-	O	O
binding	O	O
sites	O	O
when	O	O
compared	O	O
with	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
PAX6	O	O
.	O	O

.	O	O

HFE	O	O
binds	O	O
to	O	O
transferrin	O	O
receptor	O	O
(	O	O
TfR	O	O
)	O	O
and	O	O
reduces	O	O
its	O	O
affinity	O	O
for	O	O
iron	O	O
-	O	O
loaded	O	O
transferrin	O	O
,	O	O
implicating	O	O
HFE	O	O
in	O	O
iron	O	O
metabolism	O	O
.	O	O

The	O	O
2	O	O
.	O	O

We	O	O
also	O	O
demonstrate	O	O
that	O	O
soluble	O	O
TfR	O	O
and	O	O
HFE	O	O
bind	O	O
tightly	O	O
at	O	O
the	O	O
basic	O	O
pH	O	O
of	O	O
the	O	O
cell	O	O
surface	O	O
,	O	O
but	O	O
not	O	O
at	O	O
the	O	O
acidic	O	O
pH	O	O
of	O	O
intracellular	O	O
vesicles	O	O
.	O	O

TfR	O	O
HFE	O	O
stoichiometry	O	O
(	O	O
2	O	O
1	O	O
)	O	O
differs	O	O
from	O	O
TfR	O	O
transferrin	O	O
stoichiometry	O	O
(	O	O
2	O	O
2	O	O
)	O	O
,	O	O
implying	O	O
a	O	O
different	O	O
mode	O	O
of	O	O
binding	O	O
for	O	O
HFE	O	O
and	O	O
transferrin	O	O
to	O	O
TfR	O	O
,	O	O
consistent	O	O
with	O	O
our	O	O
demonstration	O	O
that	O	O
HFE	O	O
,	O	O
transferrin	O	O
,	O	O
and	O	O
TfR	O	O
form	O	O
a	O	O
ternary	O	O
complex	O	O
.	O	O

Results	O	O
presented	O	O
here	O	O
show	O	O
that	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
coexist	O	O
in	O	O
a	O	O
biochemical	O	O
complex	O	O
and	O	O
colocalize	O	O
in	O	O
subnuclear	O	O
foci	O	O
in	O	O
somatic	O	O
cells	O	O
and	O	O
on	O	O
the	O	O
axial	O	O
elements	O	O
of	O	O
developing	O	O
synaptonemal	O	O
complexes	O	O
.	O	O

Like	O	O
BRCA1	O	O
and	O	O
RAD51	O	O
,	O	O
BRCA2	O	O
relocates	O	O
to	O	O
PCNA	O	O
+	O	O
replication	O	O
sites	O	O
following	O	O
exposure	O	O
of	O	O
S	O	O
phase	O	O
cells	O	O
to	O	O
hydroxyurea	O	O
or	O	O
UV	O	O
irradiation	O	O
.	O	O

Thus	O	O
,	O	O
BRCA1	O	O
and	O	O
BRCA2	O	O
participate	O	O
,	O	O
together	O	O
,	O	O
in	O	O
a	O	O
pathway	O	O
(	O	O
s	O	O
)	O	O
associated	O	O
with	O	O
the	O	O
activation	O	O
of	O	O
double	O	O
-	O	O
strand	O	O
break	O	O
repair	O	O
and	O	O
/	O	O
or	O	O
homologous	O	O
recombination	O	O
.	O	O

.	O	O

A	O	O
novel	O	O
Arg362Ser	O	O
mutation	O	O
in	O	O
the	O	O
sterol	O	O
27	O	O
-	O	O
hydroxylase	O	O
gene	O	O
(	O	O
CYP27	O	O
)	O	O
:	O	O
its	O	O
effects	O	O
on	O	O
pre	O	O
-	O	O
mRNA	O	O
splicing	O	O
and	O	O
enzyme	O	O
activity	O	O
.	O	O

Quantitative	O	O
analysis	O	O
showed	O	O
that	O	O
the	O	O
expression	O	O
of	O	O
CYP27	O	O
gene	O	O
mRNA	O	O
in	O	O
the	O	O
patient	O	O
represented	O	O
52	O	O
.	O	O

5	O	O
%	O	O
of	O	O
the	O	O
normal	O	O
level	O	O
.	O	O

As	O	O
the	O	O
mutation	O	O
occurred	O	O
at	O	O
the	O	O
penultimate	O	O
nucleotide	O	O
of	O	O
exon	O	O
6	O	O
(	O	O
-	O	O
2	O	O
position	O	O
of	O	O
exon	O	O
6	O	O
-	O	O
intron	O	O
6	O	O
splice	O	O
site	O	O
)	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
we	O	O
hypothesized	O	O
that	O	O
the	O	O
mutation	O	O
may	O	O
partially	O	O
affect	O	O
the	O	O
normal	O	O
splicing	O	O
efficiency	O	O
in	O	O
exon	O	O
6	O	O
and	O	O
cause	O	O
alternative	O	O
splicing	O	O
elsewhere	O	O
,	O	O
which	O	O
resulted	O	O
in	O	O
decreased	O	O
transcript	O	O
in	O	O
the	O	O
patient	O	O
.	O	O

Transfection	O	O
of	O	O
constructed	O	O
minigenes	O	O
,	O	O
with	O	O
or	O	O
without	O	O
the	O	O
mutation	O	O
,	O	O
into	O	O
COS	O	O
-	O	O
1	O	O
cells	O	O
confirmed	O	O
that	O	O
the	O	O
mutant	O	O
minigene	O	O
was	O	O
responsible	O	O
for	O	O
a	O	O
mRNA	O	O
species	O	O
alternatively	O	O
spliced	O	O
at	O	O
an	O	O
activated	O	O
cryptic	O	O
5	O	O
splice	O	O
site	O	O
88	O	O
bp	O	O
upstream	O	O
from	O	O
the	O	O
3	O	O
end	O	O
of	O	O
exon	O	O
6	O	O
.	O	O

To	O	O
our	O	O
knowledge	O	O
,	O	O
this	O	O
is	O	O
the	O	O
first	O	O
report	O	O
regarding	O	O
effects	O	O
on	O	O
pre	O	O
-	O	O
mRNA	O	O
splicing	O	O
of	O	O
a	O	O
mutation	O	O
at	O	O
the	O	O
-	O	O
2	O	O
position	O	O
of	O	O
a	O	O
5	O	O
splice	O	O
site	O	O
.	O	O

A	O	O
variety	O	O
of	O	O
phenotypes	O	O
were	O	O
observed	O	O
within	O	O
this	O	O
family	O	O
.	O	O

Another	O	O
nephew	O	O
(	O	O
patient	O	O
4	O	O
)	O	O
of	O	O
patient	O	O
1	O	O
was	O	O
classified	O	O
as	O	O
having	O	O
an	O	O
adolescent	O	O
form	O	O
.	O	O

Oleic	O	O
and	O	O
erucic	O	O
acids	O	O
(	O	O
Lorenzos	O	O
Oil	O	O
)	O	O
were	O	O
administered	O	O
to	O	O
patients	O	O
1	O	O
and	O	O
4	O	O
,	O	O
but	O	O
sufficient	O	O
effectiveness	O	O
was	O	O
not	O	O
obtained	O	O
.	O	O

Lorenzos	O	O
Oil	O	O
should	O	O
be	O	O
given	O	O
in	O	O
the	O	O
early	O	O
stage	O	O
.	O	O

.	O	O

1	O	O
and	O	O
,	O	O
recently	O	O
,	O	O
found	O	O
to	O	O
encode	O	O
a	O	O
putative	O	O
sulfate	O	O
transporter	O	O
.	O	O

The	O	O
mutations	O	O
include	O	O
three	O	O
single	O	O
base	O	O
deletions	O	O
,	O	O
one	O	O
splice	O	O
site	O	O
mutation	O	O
and	O	O
10	O	O
missense	O	O
mutations	O	O
.	O	O

One	O	O
missense	O	O
mutation	O	O
(	O	O
L236P	O	O
)	O	O
was	O	O
found	O	O
in	O	O
a	O	O
homozygous	O	O
state	O	O
in	O	O
two	O	O
consanguineous	O	O
families	O	O
and	O	O
in	O	O
a	O	O
heterozygous	O	O
state	O	O
in	O	O
five	O	O
additional	O	O
non	O	O
-	O	O
consanguineous	O	O
families	O	O
.	O	O

Another	O	O
missense	O	O
mutation	O	O
(	O	O
T416P	O	O
)	O	O
was	O	O
found	O	O
in	O	O
a	O	O
homozygous	O	O
state	O	O
in	O	O
one	O	O
family	O	O
and	O	O
in	O	O
a	O	O
heterozygous	O	O
state	O	O
in	O	O
four	O	O
families	O	O
.	O	O

In	O	O
total	O	O
,	O	O
one	O	O
or	O	O
both	O	O
of	O	O
these	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
nine	O	O
of	O	O
the	O	O
14	O	O
families	O	O
analyzed	O	O
.	O	O

However	O	O
,	O	O
since	O	O
these	O	O
patients	O	O
excrete	O	O
early	O	O
large	O	O
amounts	O	O
of	O	O
aspartylglucosamine	O	O
in	O	O
urine	O	O
,	O	O
biochemical	O	O
screening	O	O
is	O	O
easy	O	O
by	O	O
urine	O	O
chromatography	O	O
.	O	O

.	O	O

Mutation	O	O
spectrum	O	O
and	O	O
genotype	O	O
-	O	O
phenotype	O	O
analyses	O	O
in	O	O
Cowden	B-Disease	D006223
disease	I-Disease	D006223
and	O	O
Bannayan	B-Disease	D006223
-	I-Disease	D006223
Zonana	I-Disease	D006223
syndrome	I-Disease	D006223
,	O	O
two	O	O
hamartoma	B-Disease	D006223
syndromes	I-Disease	D006223
with	O	O
germline	O	O
PTEN	O	O
mutation	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
PTEN	O	O
was	O	O
identified	O	O
as	O	O
the	O	O
susceptibility	O	O
gene	O	O
for	O	O
two	O	O
hamartoma	B-Disease	D006223
syndromes	I-Disease	D006223
Cowden	B-Disease	D006223
disease	I-Disease	D006223
(	O	O
CD	B-Disease	D006223
;	O	O
MIM	O	O
158350	O	O
)	O	O
and	O	O
Bannayan	B-Disease	D006223
-	I-Disease	D006223
Zonana	I-Disease	D006223
(	I-Disease	D006223
BZS	I-Disease	D006223
)	I-Disease	D006223
or	I-Disease	D006223
Ruvalcaba	I-Disease	D006223
-	I-Disease	D006223
Riley	I-Disease	D006223
-	I-Disease	D006223
Smith	I-Disease	D006223
syndrome	I-Disease	D006223
(	O	O
MIM	O	O
153480	O	O
)	O	O
.	O	O

Constitutive	O	O
DNA	O	O
from	O	O
37	O	O
CD	B-Disease	D006223
families	O	O
and	O	O
seven	O	O
BZS	B-Disease	D006223
families	O	O
was	O	O
screened	O	O
for	O	O
germline	O	O
PTEN	O	O
mutations	O	O
.	O	O

PTEN	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
30	O	O
of	O	O
37	O	O
(	O	O
81	O	O
%	O	O
)	O	O
CD	B-Disease	D006223
families	O	O
,	O	O
including	O	O
missense	O	O
and	O	O
nonsense	O	O
point	O	O
mutations	O	O
,	O	O
deletions	O	O
,	O	O
insertions	O	O
,	O	O
a	O	O
deletion	O	O
/	O	O
insertion	O	O
and	O	O
splice	O	O
site	O	O
mutations	O	O
.	O	O

These	O	O
mutations	O	O
were	O	O
scattered	O	O
over	O	O
the	O	O
entire	O	O
length	O	O
of	O	O
PTEN	O	O
,	O	O
with	O	O
the	O	O
exception	O	O
of	O	O
the	O	O
first	O	O
,	O	O
fourth	O	O
and	O	O
last	O	O
exons	O	O
.	O	O

A	O	O
hot	O	O
spot	O	O
for	O	O
PTEN	O	O
mutation	O	O
in	O	O
CD	B-Disease	D006223
was	O	O
identified	O	O
in	O	O
exon	O	O
5	O	O
that	O	O
contains	O	O
the	O	O
PTPase	O	O
core	O	O
motif	O	O
,	O	O
with	O	O
13	O	O
of	O	O
30	O	O
(	O	O
43	O	O
%	O	O
)	O	O
CD	B-Disease	D006223
mutations	O	O
identified	O	O
in	O	O
this	O	O
exon	O	O
.	O	O

Seven	O	O
of	O	O
30	O	O
(	O	O
23	O	O
%	O	O
)	O	O
were	O	O
within	O	O
the	O	O
core	O	O
motif	O	O
,	O	O
the	O	O
majority	O	O
(	O	O
five	O	O
of	O	O
seven	O	O
)	O	O
of	O	O
which	O	O
were	O	O
missense	O	O
mutations	O	O
,	O	O
possibly	O	O
pointing	O	O
to	O	O
the	O	O
functional	O	O
significance	O	O
of	O	O
this	O	O
region	O	O
.	O	O

Germline	O	O
PTEN	O	O
mutations	O	O
were	O	O
identified	O	O
in	O	O
four	O	O
of	O	O
seven	O	O
(	O	O
57	O	O
%	O	O
)	O	O
BZS	B-Disease	D006223
families	O	O
studied	O	O
.	O	O

Interestingly	O	O
,	O	O
none	O	O
of	O	O
these	O	O
mutations	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
PTPase	O	O
core	O	O
motif	O	O
.	O	O

It	O	O
is	O	O
also	O	O
worthy	O	O
of	O	O
note	O	O
that	O	O
a	O	O
single	O	O
nonsense	O	O
point	O	O
mutation	O	O
,	O	O
R233X	O	O
,	O	O
was	O	O
observed	O	O
in	O	O
the	O	O
germline	O	O
DNA	O	O
from	O	O
two	O	O
unrelated	O	O
CD	B-Disease	D006223
families	O	O
and	O	O
one	O	O
BZS	B-Disease	D006223
family	O	O
.	O	O

Genotype	O	O
-	O	O
phenotype	O	O
studies	O	O
were	O	O
not	O	O
performed	O	O
on	O	O
this	O	O
small	O	O
group	O	O
of	O	O
BZS	B-Disease	D006223
families	O	O
.	O	O

However	O	O
,	O	O
genotype	O	O
-	O	O
phenotype	O	O
analysis	O	O
inthe	O	O
group	O	O
of	O	O
CD	B-Disease	D006223
families	O	O
revealed	O	O
two	O	O
possible	O	O
associations	O	O
worthy	O	O
of	O	O
follow	O	O
-	O	O
up	O	O
in	O	O
independent	O	O
analyses	O	O
.	O	O

The	O	O
first	O	O
was	O	O
an	O	O
association	O	O
noted	O	O
in	O	O
the	O	O
group	O	O
of	O	O
CD	B-Disease	D006223
families	O	O
with	O	O
breast	B-Disease	D001941
disease	I-Disease	D001941
.	O	O

A	O	O
correlation	O	O
was	O	O
observed	O	O
between	O	O
the	O	O
presence	O	O
/	O	O
absence	O	O
of	O	O
a	O	O
PTEN	O	O
mutation	O	O
and	O	O
the	O	O
type	O	O
of	O	O
breast	O	O
involvement	O	O
(	O	O
unaffected	O	O
versus	O	O
benign	O	O
versus	O	O
malignant	O	O
)	O	O
.	O	O

Specifically	O	O
and	O	O
more	O	O
directly	O	O
,	O	O
an	O	O
association	O	O
was	O	O
also	O	O
observed	O	O
between	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
PTEN	O	O
mutation	O	O
and	O	O
malignant	B-Disease	D001941
breast	I-Disease	D001941
disease	I-Disease	D001941
.	O	O

Secondly	O	O
,	O	O
there	O	O
appeared	O	O
to	O	O
be	O	O
an	O	O
interdependent	O	O
association	O	O
between	O	O
mutations	O	O
upstream	O	O
and	O	O
within	O	O
the	O	O
PTPase	O	O
core	O	O
motif	O	O
,	O	O
the	O	O
core	O	O
motif	O	O
containing	O	O
the	O	O
majority	O	O
of	O	O
missense	O	O
mutations	O	O
,	O	O
and	O	O
the	O	O
involvement	O	O
of	O	O
all	O	O
major	O	O
organ	O	O
systems	O	O
(	O	O
central	O	O
nervous	O	O
system	O	O
,	O	O
thyroid	O	O
,	O	O
breast	O	O
,	O	O
skin	O	O
and	O	O
gastrointestinal	O	O
tract	O	O
)	O	O
.	O	O

However	O	O
,	O	O
these	O	O
observations	O	O
would	O	O
need	O	O
to	O	O
be	O	O
confirmed	O	O
by	O	O
studying	O	O
a	O	O
larger	O	O
number	O	O
of	O	O
CD	B-Disease	D006223
families	O	O
.	O	O

The	O	O
I1307K	O	O
polymorphism	O	O
has	O	O
previously	O	O
only	O	O
been	O	O
identified	O	O
in	O	O
individuals	O	O
of	O	O
self	O	O
-	O	O
reported	O	O
Ashkenazi	O	O
Jewish	O	O
origins	O	O
.	O	O

.	O	O

In	O	O
males	O	O
,	O	O
SF	O	O
-	O	O
1	O	O
participates	O	O
in	O	O
sexual	O	O
development	O	O
by	O	O
regulating	O	O
expression	O	O
of	O	O
the	O	O
polypeptide	O	O
hormone	O	O
Mullerian	O	O
inhibiting	O	O
substance	O	O
(	O	O
MIS	O	O
)	O	O
.	O	O

Here	O	O
,	O	O
we	O	O
show	O	O
that	O	O
WT1	O	O
-	O	O
KTS	O	O
isoforms	O	O
associate	O	O
and	O	O
synergize	O	O
with	O	O
SF	O	O
-	O	O
1	O	O
to	O	O
promote	O	O
MIS	O	O
expression	O	O
.	O	O

Additionally	O	O
,	O	O
the	O	O
X	O	O
-	O	O
linked	O	O
,	O	O
candidate	O	O
dosage	O	O
-	O	O
sensitive	O	O
sex	O	O
-	O	O
reversal	O	O
gene	O	O
,	O	O
Dax	O	O
-	O	O
1	O	O
,	O	O
antagonizes	O	O
synergy	O	O
between	O	O
SF	O	O
-	O	O
1	O	O
and	O	O
WT1	O	O
,	O	O
most	O	O
likely	O	O
through	O	O
a	O	O
direct	O	O
interaction	O	O
with	O	O
SF	O	O
-	O	O
1	O	O
.	O	O

We	O	O
propose	O	O
that	O	O
WT1	O	O
and	O	O
Dax	O	O
-	O	O
1	O	O
functionally	O	O
oppose	O	O
each	O	O
other	O	O
in	O	O
testis	O	O
development	O	O
by	O	O
modulating	O	O
SF	O	O
-	O	O
1	O	O
-	O	O
mediated	O	O
transactivation	O	O
.	O	O

.	O	O

Ethnic	O	O
differences	O	O
in	O	O
the	O	O
HFE	O	O
codon	O	O
282	O	O
(	O	O
Cys	O	O
/	O	O
Tyr	O	O
)	O	O
polymorphism	O	O
.	O	O

5	O	O
Mb	O	O
telomeric	O	O
to	O	O
HLA	O	O
-	O	O
A	O	O
.	O	O

Population	O	O
studies	O	O
of	O	O
this	O	O
polymorphism	O	O
are	O	O
facilitated	O	O
by	O	O
the	O	O
fact	O	O
that	O	O
the	O	O
Cys282Tyr	O	O
mutation	O	O
creates	O	O
a	O	O
Rsal	O	O
restriction	O	O
site	O	O
.	O	O

We	O	O
have	O	O
studied	O	O
the	O	O
codon	O	O
282	O	O
(	O	O
Cys	O	O
/	O	O
Tyr	O	O
)	O	O
polymorphism	O	O
in	O	O
different	O	O
ethnic	O	O
groups	O	O
.	O	O

In	O	O
agreement	O	O
with	O	O
previous	O	O
observations	O	O
the	O	O
Tyr	O	O
allele	O	O
appeared	O	O
to	O	O
be	O	O
rare	O	O
or	O	O
absent	O	O
in	O	O
Asiatic	O	O
(	O	O
Indian	O	O
,	O	O
Chinese	O	O
)	O	O
populations	O	O
.	O	O

The	O	O
highest	O	O
allele	O	O
frequency	O	O
(	O	O
7	O	O
.	O	O

5	O	O
%	O	O
)	O	O
was	O	O
found	O	O
in	O	O
Swedes	O	O
.	O	O

Saamis	O	O
(	O	O
2	O	O
%	O	O
)	O	O
and	O	O
Mordvinians	O	O
(	O	O
1	O	O
.	O	O

8	O	O
%	O	O
)	O	O
had	O	O
significantly	O	O
lower	O	O
frequencies	O	O
of	O	O
the	O	O
Tyr	O	O
allele	O	O
.	O	O

Limits	O	O
to	O	O
accuracy	O	O
included	O	O
recombination	O	O
between	O	O
the	O	O
DNA	O	O
markers	O	O
and	O	O
the	O	O
mutation	O	O
,	O	O
pedigree	O	O
structure	O	O
,	O	O
and	O	O
whether	O	O
DNA	O	O
samples	O	O
were	O	O
available	O	O
from	O	O
family	O	O
members	O	O
.	O	O

For	O	O
six	O	O
such	O	O
individuals	O	O
,	O	O
there	O	O
was	O	O
significant	O	O
disparity	O	O
between	O	O
the	O	O
tests	O	O
.	O	O

Three	O	O
went	O	O
from	O	O
a	O	O
decreased	O	O
risk	O	O
to	O	O
an	O	O
increased	O	O
risk	O	O
,	O	O
while	O	O
in	O	O
another	O	O
three	O	O
the	O	O
risk	O	O
was	O	O
decreased	O	O
.	O	O

Knowledge	O	O
of	O	O
the	O	O
potential	O	O
reasons	O	O
for	O	O
these	O	O
changes	O	O
in	O	O
results	O	O
and	O	O
impact	O	O
of	O	O
these	O	O
risk	O	O
reversals	O	O
on	O	O
both	O	O
patients	O	O
and	O	O
the	O	O
counseling	O	O
team	O	O
can	O	O
assist	O	O
in	O	O
the	O	O
development	O	O
of	O	O
strategies	O	O
for	O	O
the	O	O
prevention	O	O
and	O	O
,	O	O
where	O	O
necessary	O	O
,	O	O
management	O	O
of	O	O
a	O	O
risk	O	O
reversal	O	O
in	O	O
any	O	O
predictive	O	O
testing	O	O
program	O	O
.	O	O

.	O	O

Arg778Leu	O	O
,	O	O
the	O	O
most	O	O
frequently	O	O
reported	O	O
mutation	O	O
of	O	O
this	O	O
enzyme	O	O
,	O	O
was	O	O
found	O	O
in	O	O
six	O	O
of	O	O
eight	O	O
unrelated	O	O
patients	O	O
studied	O	O
,	O	O
an	O	O
allele	O	O
frequency	O	O
of	O	O
37	O	O
.	O	O

5	O	O
%	O	O
,	O	O
which	O	O
is	O	O
considerably	O	O
higher	O	O
than	O	O
those	O	O
in	O	O
other	O	O
Asian	O	O
populations	O	O
.	O	O

The	O	O
novel	O	O
single	O	O
nucleotide	O	O
deletion	O	O
,	O	O
2304delC	O	O
,	O	O
was	O	O
found	O	O
in	O	O
one	O	O
patient	O	O
.	O	O

Determination	O	O
of	O	O
the	O	O
genomic	O	O
structure	O	O
of	O	O
the	O	O
COL4A4	O	O
gene	O	O
and	O	O
of	O	O
novel	O	O
mutations	O	O
causing	O	O
autosomal	B-Disease	C536587
recessive	I-Disease	C536587
Alport	I-Disease	C536587
syndrome	I-Disease	C536587
.	O	O

To	O	O
date	O	O
,	O	O
mutation	O	O
screening	O	O
in	O	O
the	O	O
two	O	O
genes	O	O
has	O	O
been	O	O
hampered	O	O
by	O	O
the	O	O
lack	O	O
of	O	O
genomic	O	O
structure	O	O
information	O	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
complete	O	O
characterization	O	O
of	O	O
the	O	O
48	O	O
exons	O	O
of	O	O
the	O	O
COL4A4	O	O
gene	O	O
,	O	O
a	O	O
comprehensive	O	O
gene	O	O
screen	O	O
,	O	O
and	O	O
the	O	O
subsequent	O	O
detection	O	O
of	O	O
10	O	O
novel	O	O
mutations	O	O
in	O	O
eight	O	O
patients	O	O
diagnosed	O	O
with	O	O
autosomal	B-Disease	C536587
recessive	I-Disease	C536587
Alport	I-Disease	C536587
syndrome	I-Disease	C536587
.	O	O

Furthermore	O	O
,	O	O
we	O	O
identified	O	O
a	O	O
glycine	O	O
to	O	O
alanine	O	O
substitution	O	O
in	O	O
the	O	O
collagenous	O	O
domain	O	O
that	O	O
is	O	O
apparently	O	O
silent	O	O
in	O	O
the	O	O
heterozygous	O	O
carriers	O	O
,	O	O
in	O	O
11	O	O
.	O	O

5	O	O
%	O	O
of	O	O
all	O	O
control	O	O
individuals	O	O
,	O	O
and	O	O
in	O	O
one	O	O
control	O	O
individual	O	O
homozygous	O	O
for	O	O
this	O	O
glycine	O	O
substitution	O	O
.	O	O

There	O	O
has	O	O
been	O	O
no	O	O
previous	O	O
finding	O	O
of	O	O
a	O	O
glycine	O	O
substitution	O	O
that	O	O
is	O	O
not	O	O
associated	O	O
with	O	O
any	O	O
obvious	O	O
phenotype	O	O
in	O	O
homozygous	O	O
individuals	O	O
.	O	O

Linkage	O	O
to	O	O
markers	O	O
on	O	O
chromosome	O	O
4p	O	O
was	O	O
confirmed	O	O
in	O	O
five	O	O
families	O	O
.	O	O

WFS1	O	O
appears	O	O
to	O	O
function	O	O
in	O	O
survival	O	O
of	O	O
islet	O	O
beta	O	O
-	O	O
cells	O	O
and	O	O
neurons	O	O
.	O	O

.	O	O

By	O	O
using	O	O
exon	O	O
-	O	O
specific	O	O
polymerase	O	O
chain	O	O
reaction	O	O
(	O	O
PCR	O	O
)	O	O
/	O	O
single	O	O
-	O	O
strand	O	O
conformation	O	O
polymorphism	O	O
as	O	O
a	O	O
screening	O	O
step	O	O
and	O	O
nucleotide	O	O
sequencing	O	O
of	O	O
target	O	O
exons	O	O
,	O	O
we	O	O
determined	O	O
that	O	O
the	O	O
proband	O	O
was	O	O
a	O	O
compound	O	O
heterozygote	O	O
for	O	O
two	O	O
C6	O	O
gene	O	O
mutations	O	O
.	O	O

Both	O	O
mutations	O	O
result	O	O
in	O	O
premature	O	O
termination	O	O
codons	O	O
and	O	O
C6	O	O
null	O	O
alleles	O	O
.	O	O

Allele	O	O
-	O	O
specific	O	O
PCR	O	O
indicated	O	O
that	O	O
the	O	O
probands	O	O
two	O	O
brothers	O	O
also	O	O
inherited	O	O
the	O	O
1195delC	O	O
mutation	O	O
from	O	O
their	O	O
heterozygous	O	O
mother	O	O
and	O	O
the	O	O
1936delG	O	O
mutation	O	O
from	O	O
their	O	O
homozygous	O	O
father	O	O
.	O	O

.	O	O

Occasionally	O	O
,	O	O
a	O	O
fully	O	O
expanded	O	O
allele	O	O
has	O	O
been	O	O
found	O	O
to	O	O
arise	O	O
from	O	O
a	O	O
premutation	O	O
of	O	O
100	O	O
or	O	O
less	O	O
triplet	O	O
repeats	O	O
.	O	O

We	O	O
have	O	O
examined	O	O
the	O	O
sperm	O	O
DNA	O	O
of	O	O
a	O	O
premutation	O	O
carrier	O	O
.	O	O

This	O	O
mans	O	O
leucocyte	O	O
DNA	O	O
showed	O	O
one	O	O
normal	O	O
allele	O	O
and	O	O
one	O	O
allele	O	O
of	O	O
approximately	O	O
100	O	O
repeats	O	O
.	O	O

His	O	O
sperm	O	O
showed	O	O
an	O	O
expanded	O	O
allele	O	O
in	O	O
a	O	O
tight	O	O
range	O	O
centering	O	O
on	O	O
a	O	O
size	O	O
of	O	O
approximately	O	O
320	O	O
trinucleotide	O	O
repeats	O	O
.	O	O

His	O	O
affected	O	O
son	O	O
has	O	O
repeat	O	O
sizes	O	O
of	O	O
1040	O	O
and	O	O
540	O	O
.	O	O

These	O	O
data	O	O
suggest	O	O
that	O	O
expansion	O	O
occurs	O	O
in	O	O
two	O	O
stages	O	O
,	O	O
the	O	O
first	O	O
during	O	O
meiosis	O	O
followed	O	O
by	O	O
a	O	O
second	O	O
mitotic	O	O
expansion	O	O
.	O	O

We	O	O
also	O	O
show	O	O
that	O	O
in	O	O
all	O	O
informative	O	O
carrier	O	O
father	O	O
to	O	O
affected	O	O
child	O	O
transmissions	O	O
,	O	O
with	O	O
the	O	O
notable	O	O
exception	O	O
of	O	O
the	O	O
premutation	O	O
carrier	O	O
,	O	O
the	O	O
expansion	O	O
size	O	O
decreases	O	O
.	O	O

.	O	O

The	O	O
smooth	O	O
pursuit	O	O
gain	O	O
was	O	O
decreased	O	O
.	O	O

In	O	O
SCA2	B-Disease	OMIM:183090
,	O	O
saccade	O	O
velocity	O	O
was	O	O
markedly	O	O
decreased	O	O
.	O	O

The	O	O
percentage	O	O
of	O	O
errors	O	O
in	O	O
antisaccades	O	O
was	O	O
greatly	O	O
increased	O	O
and	O	O
was	O	O
significantly	O	O
correlated	O	O
with	O	O
age	O	O
at	O	O
disease	O	O
onset	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
a	O	O
correlation	O	O
between	O	O
smooth	O	O
pursuit	O	O
gain	O	O
and	O	O
the	O	O
number	O	O
of	O	O
trinucleotide	O	O
repeats	O	O
was	O	O
found	O	O
.	O	O

.	O	O

3	O	O
)	O	O
.	O	O

These	O	O
clustered	O	O
in	O	O
the	O	O
region	O	O
corresponding	O	O
to	O	O
the	O	O
kinase	O	O
domain	O	O
,	O	O
which	O	O
is	O	O
highly	O	O
conserved	O	O
in	O	O
ATM	O	O
-	O	O
related	O	O
proteins	O	O
in	O	O
mouse	O	O
,	O	O
yeast	O	O
and	O	O
Drosophila	O	O
.	O	O

The	O	O
resulting	O	O
amino	O	O
-	O	O
acid	O	O
substitutions	O	O
are	O	O
predicted	O	O
to	O	O
interfere	O	O
with	O	O
ATP	O	O
binding	O	O
or	O	O
substrate	O	O
recognition	O	O
.	O	O

As	O	O
constitutional	O	O
DNA	O	O
was	O	O
not	O	O
available	O	O
,	O	O
a	O	O
putative	O	O
hereditary	O	O
predisposition	O	O
to	O	O
T	B-Disease	D015461
-	I-Disease	D015461
PLL	I-Disease	D015461
will	O	O
require	O	O
further	O	O
investigation	O	O
.	O	O

.	O	O

In	O	O
one	O	O
of	O	O
the	O	O
families	O	O
,	O	O
affected	O	O
individuals	O	O
presented	O	O
a	O	O
novel	O	O
nonsense	O	O
mutation	O	O
in	O	O
exon	O	O
3	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
consisting	O	O
in	O	O
a	O	O
G	O	O
to	O	O
T	O	O
transition	O	O
at	O	O
nucleotide	O	O
2101	O	O
,	O	O
which	O	O
produces	O	O
a	O	O
stop	O	O
signal	O	O
in	O	O
codon	O	O
82	O	O
(	O	O
Glu	O	O
)	O	O
of	O	O
NPII	O	O
.	O	O

The	O	O
premature	O	O
termination	O	O
eliminates	O	O
part	O	O
of	O	O
the	O	O
C	O	O
-	O	O
terminal	O	O
domain	O	O
of	O	O
NPII	O	O
,	O	O
including	O	O
a	O	O
cysteine	O	O
residue	O	O
in	O	O
position	O	O
85	O	O
,	O	O
which	O	O
could	O	O
be	O	O
involved	O	O
in	O	O
the	O	O
correct	O	O
folding	O	O
of	O	O
the	O	O
prohormone	O	O
.	O	O

In	O	O
the	O	O
second	O	O
family	O	O
,	O	O
a	O	O
G279A	O	O
substitution	O	O
at	O	O
position	O	O
-	O	O
1	O	O
of	O	O
the	O	O
signal	O	O
peptide	O	O
was	O	O
observed	O	O
in	O	O
all	O	O
affected	O	O
individuals	O	O
.	O	O

.	O	O

Cloning	O	O
of	O	O
a	O	O
novel	O	O
member	O	O
of	O	O
the	O	O
low	O	O
-	O	O
density	O	O
lipoprotein	O	O
receptor	O	O
family	O	O
.	O	O

The	O	O
gene	O	O
,	O	O
termed	O	O
low	O	O
-	O	O
density	O	O
lipoprotein	O	O
receptor	O	O
related	O	O
protein	O	O
5	O	O
(	O	O
LRP5	O	O
)	O	O
,	O	O
encodes	O	O
a	O	O
protein	O	O
of	O	O
1615	O	O
amino	O	O
acids	O	O
that	O	O
contains	O	O
conserved	O	O
modules	O	O
which	O	O
are	O	O
characteristic	O	O
of	O	O
the	O	O
low	O	O
-	O	O
density	O	O
lipoprotein	O	O
(	O	O
LDL	O	O
)	O	O
receptor	O	O
family	O	O
.	O	O

These	O	O
modules	O	O
include	O	O
a	O	O
putative	O	O
signal	O	O
peptide	O	O
for	O	O
protein	O	O
export	O	O
,	O	O
four	O	O
epidermal	O	O
growth	O	O
factor	O	O
(	O	O
EGF	O	O
)	O	O
repeats	O	O
with	O	O
associated	O	O
spacer	O	O
domains	O	O
,	O	O
three	O	O
LDL	O	O
-	O	O
receptor	O	O
(	O	O
LDLR	O	O
)	O	O
repeats	O	O
,	O	O
a	O	O
single	O	O
transmembrane	O	O
spanning	O	O
domain	O	O
,	O	O
and	O	O
a	O	O
cytoplasmic	O	O
domain	O	O
.	O	O

The	O	O
encoded	O	O
protein	O	O
has	O	O
a	O	O
unique	O	O
organization	O	O
of	O	O
EGF	O	O
and	O	O
LDLR	O	O
repeats	O	O
;	O	O
therefore	O	O
,	O	O
LRP5	O	O
likely	O	O
represents	O	O
a	O	O
new	O	O
category	O	O
of	O	O
the	O	O
LDLR	O	O
family	O	O
.	O	O

Both	O	O
human	O	O
and	O	O
mouse	O	O
LRP5	O	O
cDNAs	O	O
have	O	O
been	O	O
isolated	O	O
and	O	O
the	O	O
encoded	O	O
mature	O	O
proteins	O	O
are	O	O
95	O	O
%	O	O
identical	O	O
,	O	O
indicating	O	O
a	O	O
high	O	O
degree	O	O
of	O	O
evolutionary	O	O
conservation	O	O
.	O	O

.	O	O

Both	O	O
the	O	O
protein	O	O
truncation	O	O
test	O	O
(	O	O
PTT	O	O
)	O	O
and	O	O
the	O	O
restriction	O	O
endonuclease	O	O
fingerprinting	O	O
(	O	O
REF	O	O
)	O	O
method	O	O
were	O	O
used	O	O
and	O	O
compared	O	O
for	O	O
their	O	O
detection	O	O
efficiency	O	O
,	O	O
identifying	O	O
76	O	O
%	O	O
and	O	O
60	O	O
%	O	O
of	O	O
the	O	O
mutations	O	O
,	O	O
respectively	O	O
.	O	O

Most	O	O
patients	O	O
were	O	O
found	O	O
to	O	O
be	O	O
compound	O	O
heterozygote	O	O
.	O	O

Seventeen	O	O
mutations	O	O
were	O	O
distinct	O	O
,	O	O
of	O	O
which	O	O
10	O	O
were	O	O
not	O	O
reported	O	O
previously	O	O
.	O	O

Mutations	O	O
are	O	O
small	O	O
deletions	O	O
or	O	O
point	O	O
mutations	O	O
frequently	O	O
affecting	O	O
splice	O	O
sites	O	O
.	O	O

Moreover	O	O
,	O	O
a	O	O
16	O	O
.	O	O

7	O	O
-	O	O
kb	O	O
genomic	O	O
deletion	O	O
of	O	O
the	O	O
3	O	O
end	O	O
of	O	O
the	O	O
gene	O	O
,	O	O
most	O	O
likely	O	O
a	O	O
result	O	O
of	O	O
recombination	O	O
between	O	O
two	O	O
LINE	O	O
elements	O	O
,	O	O
was	O	O
identified	O	O
.	O	O

The	O	O
presence	O	O
of	O	O
a	O	O
founder	O	O
mutation	O	O
among	O	O
relatively	O	O
small	O	O
ethnic	O	O
population	O	O
groups	O	O
in	O	O
Western	O	O
Europe	O	O
could	O	O
indicate	O	O
a	O	O
high	O	O
carrier	O	O
frequency	O	O
in	O	O
such	O	O
communities	O	O
.	O	O

In	O	O
patients	O	O
of	O	O
Dutch	O	O
ethnic	O	O
origin	O	O
,	O	O
however	O	O
,	O	O
no	O	O
significant	O	O
founder	O	O
effect	O	O
could	O	O
be	O	O
identified	O	O
.	O	O

The	O	O
observed	O	O
genetic	O	O
heterogeneity	O	O
including	O	O
the	O	O
relative	O	O
high	O	O
percentage	O	O
of	O	O
splice	O	O
-	O	O
site	O	O
mutations	O	O
had	O	O
no	O	O
reflection	O	O
on	O	O
the	O	O
phenotype	O	O
.	O	O

The	O	O
cornerstone	O	O
of	O	O
screening	O	O
and	O	O
case	O	O
detection	O	O
is	O	O
the	O	O
measurement	O	O
of	O	O
serum	O	O
transferrin	O	O
saturation	O	O
and	O	O
the	O	O
serum	O	O
ferritin	O	O
level	O	O
.	O	O

.	O	O

PAX6	O	O
mutations	O	O
reviewed	O	O
.	O	O

Twenty	O	O
-	O	O
eight	O	O
percent	O	O
of	O	O
identified	O	O
PAX6	O	O
mutations	O	O
are	O	O
C	O	O
-	O	O
T	O	O
changes	O	O
at	O	O
CpG	O	O
dinucleotides	O	O
,	O	O
20	O	O
%	O	O
are	O	O
splicing	O	O
errors	O	O
,	O	O
and	O	O
more	O	O
than	O	O
30	O	O
%	O	O
are	O	O
deletion	O	O
or	O	O
insertion	O	O
events	O	O
.	O	O

There	O	O
is	O	O
a	O	O
noticeably	O	O
elevated	O	O
level	O	O
of	O	O
mutation	O	O
in	O	O
the	O	O
paired	O	O
domain	O	O
compared	O	O
with	O	O
the	O	O
rest	O	O
of	O	O
the	O	O
gene	O	O
.	O	O

Increased	O	O
mutation	O	O
in	O	O
the	O	O
homeodomain	O	O
is	O	O
accounted	O	O
for	O	O
by	O	O
the	O	O
hypermutable	O	O
CpG	O	O
dinucleotide	O	O
in	O	O
codon	O	O
240	O	O
.	O	O

Very	O	O
nearly	O	O
all	O	O
mutations	O	O
appear	O	O
to	O	O
cause	O	O
loss	O	O
of	O	O
function	O	O
of	O	O
the	O	O
mutant	O	O
allele	O	O
,	O	O
and	O	O
more	O	O
than	O	O
80	O	O
%	O	O
of	O	O
exonic	O	O
substitutions	O	O
result	O	O
in	O	O
nonsense	O	O
codons	O	O
.	O	O

In	O	O
a	O	O
gene	O	O
with	O	O
such	O	O
extraordinarily	O	O
high	O	O
sequence	O	O
conservation	O	O
throughout	O	O
evolution	O	O
,	O	O
there	O	O
are	O	O
presumed	O	O
undiscovered	O	O
missense	O	O
mutations	O	O
,	O	O
these	O	O
are	O	O
hypothesized	O	O
to	O	O
exist	O	O
in	O	O
as	O	O
-	O	O
yet	O	O
unidentified	O	O
phenotypes	O	O
.	O	O

.	O	O

Schwartz	B-Disease	C537502
-	I-Disease	C537502
Jampel	I-Disease	C537502
syndrome	I-Disease	C537502
type	I-Disease	C537502
2	I-Disease	C537502
and	O	O
Stuve	B-Disease	C537502
-	I-Disease	C537502
Wiedemann	I-Disease	C537502
syndrome	I-Disease	C537502
:	O	O
a	O	O
case	O	O
for	O	O
"	O	O
lumping	O	O
"	O	O
.	O	O

The	O	O
similarity	O	O
of	O	O
the	O	O
clinical	O	O
and	O	O
radiographic	O	O
findings	O	O
is	O	O
so	O	O
extensive	O	O
that	O	O
these	O	O
disorders	O	O
appear	O	O
to	O	O
be	O	O
a	O	O
single	O	O
entity	O	O
.	O	O

.	O	O

The	O	O
185delAG	O	O
BRCA1	O	O
mutation	O	O
originated	O	O
before	O	O
the	O	O
dispersion	O	O
of	O	O
Jews	O	O
in	O	O
the	O	O
diaspora	O	O
and	O	O
is	O	O
not	O	O
limited	O	O
to	O	O
Ashkenazim	O	O
.	O	O

The	O	O
185delAG	O	O
mutation	O	O
in	O	O
BRCA1	O	O
is	O	O
detected	O	O
in	O	O
Ashkenazi	O	O
Jews	O	O
both	O	O
in	O	O
familial	B-Disease	OMIM:613399
breast	I-Disease	OMIM:613399
and	I-Disease	OMIM:613399
ovarian	I-Disease	OMIM:613399
cancer	I-Disease	OMIM:613399
and	O	O
in	O	O
the	O	O
general	O	O
population	O	O
.	O	O

All	O	O
tested	O	O
Ashkenazi	O	O
mutation	O	O
carriers	O	O
share	O	O
the	O	O
same	O	O
allelic	O	O
pattern	O	O
at	O	O
the	O	O
BRCA1	O	O
locus	O	O
.	O	O

Our	O	O
previous	O	O
study	O	O
showed	O	O
that	O	O
this	O	O
Ashkenazi	O	O
mutation	O	O
also	O	O
occurs	O	O
in	O	O
Iraqi	O	O
Jews	O	O
with	O	O
a	O	O
similar	O	O
allelic	O	O
pattern	O	O
.	O	O

We	O	O
extended	O	O
our	O	O
analysis	O	O
to	O	O
other	O	O
non	O	O
-	O	O
Ashkenazi	O	O
subsets	O	O
354	O	O
of	O	O
Moroccan	O	O
origin	O	O
,	O	O
200	O	O
Yemenites	O	O
and	O	O
150	O	O
Iranian	O	O
Jews	O	O
.	O	O

Heteroduplex	O	O
analysis	O	O
complemented	O	O
by	O	O
direct	O	O
DNA	O	O
sequencing	O	O
of	O	O
abnormally	O	O
migrating	O	O
bands	O	O
were	O	O
employed	O	O
.	O	O

Four	O	O
of	O	O
Moroccan	O	O
origin	O	O
(	O	O
1	O	O
.	O	O

1	O	O
%	O	O
)	O	O
and	O	O
none	O	O
of	O	O
the	O	O
Yemenites	O	O
or	O	O
Iranians	O	O
was	O	O
a	O	O
carrier	O	O
of	O	O
the	O	O
185delAG	O	O
mutation	O	O
.	O	O

Six	O	O
non	O	O
-	O	O
Ashkenazi	O	O
individuals	O	O
shared	O	O
the	O	O
common	O	O
Ashkenazi	O	O
haplotype	O	O
,	O	O
four	O	O
had	O	O
a	O	O
closely	O	O
related	O	O
pattern	O	O
,	O	O
and	O	O
the	O	O
rest	O	O
(	O	O
n	O	O
=	O	O
6	O	O
)	O	O
displayed	O	O
a	O	O
distinct	O	O
BRCA1	O	O
allelic	O	O
pattern	O	O
.	O	O

We	O	O
conclude	O	O
that	O	O
the	O	O
185delAG	O	O
BRCA1	O	O
mutation	O	O
occurs	O	O
in	O	O
some	O	O
non	O	O
-	O	O
Ashkenazi	O	O
populations	O	O
at	O	O
rates	O	O
comparable	O	O
with	O	O
that	O	O
of	O	O
Ashkenazim	O	O
.	O	O

The	O	O
majority	O	O
of	O	O
Jewish	O	O
185delAG	O	O
mutation	O	O
carriers	O	O
have	O	O
a	O	O
common	O	O
allelic	O	O
pattern	O	O
,	O	O
supporting	O	O
the	O	O
founder	O	O
effect	O	O
notion	O	O
,	O	O
but	O	O
dating	O	O
the	O	O
mutations	O	O
origin	O	O
to	O	O
an	O	O
earlier	O	O
date	O	O
than	O	O
currently	O	O
estimated	O	O
.	O	O

However	O	O
,	O	O
the	O	O
different	O	O
allelic	O	O
pattern	O	O
at	O	O
the	O	O
BRCA1	O	O
locus	O	O
even	O	O
in	O	O
some	O	O
Jewish	O	O
mutation	O	O
carriers	O	O
,	O	O
might	O	O
suggest	O	O
that	O	O
the	O	O
mutation	O	O
arose	O	O
independently	O	O
.	O	O

.	O	O

A	O	O
nonsense	O	O
mutation	O	O
in	O	O
exon	O	O
17	O	O
(	O	O
codon	O	O
556	O	O
)	O	O
of	O	O
the	O	O
RB1	O	O
gene	O	O
was	O	O
found	O	O
to	O	O
be	O	O
present	O	O
homozygously	O	O
in	O	O
both	O	O
the	O	O
retinal	B-Disease	D019572
and	I-Disease	D019572
the	I-Disease	D019572
pineal	I-Disease	D019572
tumours	I-Disease	D019572
.	O	O

The	O	O
same	O	O
mutation	O	O
was	O	O
present	O	O
heterozygously	O	O
in	O	O
the	O	O
DNA	O	O
from	O	O
the	O	O
constitutional	O	O
cells	O	O
of	O	O
the	O	O
patient	O	O
,	O	O
proving	O	O
it	O	O
to	O	O
be	O	O
of	O	O
germline	O	O
origin	O	O
.	O	O

The	O	O
initial	O	O
mutation	O	O
was	O	O
shown	O	O
to	O	O
have	O	O
occurred	O	O
in	O	O
the	O	O
paternally	O	O
derived	O	O
RB1	O	O
allele	O	O
.	O	O

.	O	O

Genomic	O	O
structure	O	O
of	O	O
the	O	O
human	O	O
congenital	B-Disease	C536210
chloride	I-Disease	C536210
diarrhea	I-Disease	C536210
(	O	O
CLD	B-Disease	C536210
)	O	O
gene	O	O
.	O	O

Congenital	B-Disease	C536210
chloride	I-Disease	C536210
diarrhea	I-Disease	C536210
(	O	O
CLD	B-Disease	C536210
)	O	O
is	O	O
caused	O	O
by	O	O
mutations	O	O
in	O	O
a	O	O
gene	O	O
which	O	O
encodes	O	O
an	O	O
intestinal	O	O
anion	O	O
transporter	O	O
.	O	O

We	O	O
report	O	O
here	O	O
the	O	O
complete	O	O
genomic	O	O
organization	O	O
of	O	O
the	O	O
human	O	O
CLD	B-Disease	C536210
gene	O	O
which	O	O
spans	O	O
approximately	O	O
39kb	O	O
,	O	O
and	O	O
comprises	O	O
21	O	O
exons	O	O
.	O	O

All	O	O
exon	O	O
/	O	O
intron	O	O
boundaries	O	O
conform	O	O
to	O	O
the	O	O
GT	O	O
/	O	O
AG	O	O
rule	O	O
.	O	O

An	O	O
analysis	O	O
of	O	O
the	O	O
putative	O	O
promoter	O	O
region	O	O
sequence	O	O
shows	O	O
a	O	O
putative	O	O
TATA	O	O
box	O	O
and	O	O
predicts	O	O
multiple	O	O
transcription	O	O
factor	O	O
binding	O	O
sites	O	O
.	O	O

The	O	O
genomic	O	O
structure	O	O
was	O	O
determined	O	O
using	O	O
DNA	O	O
from	O	O
several	O	O
sources	O	O
including	O	O
multiple	O	O
large	O	O
-	O	O
insert	O	O
libaries	O	O
and	O	O
genomic	O	O
DNA	O	O
from	O	O
Finnish	O	O
CLD	B-Disease	C536210
patients	O	O
and	O	O
controls	O	O
.	O	O

Exon	O	O
-	O	O
specific	O	O
primers	O	O
developed	O	O
in	O	O
this	O	O
study	O	O
will	O	O
facilitate	O	O
mutation	O	O
screening	O	O
studies	O	O
of	O	O
patients	O	O
with	O	O
the	O	O
disease	O	O
.	O	O

.	O	O

UBE3A	O	O
encodes	O	O
a	O	O
ubiquitin	O	O
-	O	O
protein	O	O
ligase	O	O
and	O	O
shows	O	O
brain	O	O
-	O	O
specific	O	O
imprinting	O	O
.	O	O

Two	O	O
identical	O	O
de	O	O
novo	O	O
5	O	O
-	O	O
bp	O	O
duplications	O	O
in	O	O
exon	O	O
16	O	O
were	O	O
found	O	O
.	O	O

Among	O	O
the	O	O
other	O	O
11	O	O
unique	O	O
mutations	O	O
,	O	O
8	O	O
were	O	O
small	O	O
deletions	O	O
or	O	O
insertions	O	O
predicted	O	O
to	O	O
cause	O	O
frameshifts	O	O
,	O	O
1	O	O
was	O	O
a	O	O
mutation	O	O
to	O	O
a	O	O
stop	O	O
codon	O	O
,	O	O
1	O	O
was	O	O
a	O	O
missense	O	O
mutation	O	O
,	O	O
and	O	O
1	O	O
was	O	O
predicted	O	O
to	O	O
cause	O	O
insertion	O	O
of	O	O
an	O	O
isoleucine	O	O
in	O	O
the	O	O
hect	O	O
domain	O	O
of	O	O
the	O	O
UBE3A	O	O
protein	O	O
,	O	O
which	O	O
functions	O	O
in	O	O
E2	O	O
binding	O	O
and	O	O
ubiquitin	O	O
transfer	O	O
.	O	O

Eight	O	O
of	O	O
the	O	O
cases	O	O
were	O	O
familial	O	O
,	O	O
and	O	O
five	O	O
were	O	O
sporadic	O	O
.	O	O

The	O	O
frequencies	O	O
with	O	O
which	O	O
we	O	O
detected	O	O
mutations	O	O
were	O	O
5	O	O
(	O	O
14	O	O
%	O	O
)	O	O
of	O	O
35	O	O
in	O	O
sporadic	O	O
cases	O	O
and	O	O
8	O	O
(	O	O
80	O	O
%	O	O
)	O	O
of	O	O
10	O	O
in	O	O
familial	O	O
cases	O	O
.	O	O

.	O	O

An	O	O
affected	O	O
girl	O	O
who	O	O
presented	O	O
at	O	O
9	O	O
months	O	O
of	O	O
age	O	O
and	O	O
her	O	O
similarly	O	O
affected	O	O
younger	O	O
brother	O	O
and	O	O
father	O	O
were	O	O
all	O	O
found	O	O
to	O	O
have	O	O
a	O	O
novel	O	O
missense	O	O
mutation	O	O
(	O	O
G1758	O	O
-	O	O
-	O	O
>	O	O
T	O	O
)	O	O
encoding	O	O
the	O	O
amino	O	O
acid	O	O
substitution	O	O
Gly23	O	O
-	O	O
-	O	O
>	O	O
Val	O	O
within	O	O
NPII	O	O
.	O	O

The	O	O
mutation	O	O
was	O	O
confirmed	O	O
by	O	O
restriction	O	O
endonuclease	O	O
analysis	O	O
.	O	O

A	O	O
T1	O	O
-	O	O
weighted	O	O
magnetic	O	O
resonance	O	O
imaging	O	O
of	O	O
the	O	O
fathers	O	O
pituitary	O	O
gland	O	O
demonstrates	O	O
an	O	O
attenuated	O	O
posterior	O	O
pituitary	O	O
bright	O	O
spot	O	O
.	O	O

.	O	O

Molecular	O	O
genetic	O	O
analysis	O	O
of	O	O
her	O	O
VLCAD	O	O
gene	O	O
revealed	O	O
a	O	O
T1372C	O	O
(	O	O
F458L	O	O
)	O	O
missense	O	O
mutation	O	O
and	O	O
a	O	O
1668	O	O
ACAG	O	O
1669	O	O
splice	O	O
site	O	O
mutation	O	O
.	O	O

After	O	O
initial	O	O
treatment	O	O
with	O	O
intravenous	O	O
glucose	O	O
and	O	O
carnitine	O	O
,	O	O
the	O	O
patient	O	O
has	O	O
thrived	O	O
on	O	O
a	O	O
low	O	O
-	O	O
fat	O	O
diet	O	O
supplemented	O	O
with	O	O
medium	O	O
-	O	O
chain	O	O
triglyceride	O	O
oil	O	O
and	O	O
carnitine	O	O
and	O	O
avoidance	O	O
of	O	O
fasting	O	O
.	O	O

Her	O	O
ventricular	O	O
hypertrophy	O	O
resolved	O	O
significantly	O	O
over	O	O
1	O	O
year	O	O
,	O	O
and	O	O
cognitively	O	O
,	O	O
she	O	O
is	O	O
in	O	O
the	O	O
superior	O	O
range	O	O
for	O	O
age	O	O
.	O	O

.	O	O

As	O	O
has	O	O
been	O	O
reported	O	O
by	O	O
others	O	O
,	O	O
mutations	O	O
that	O	O
lead	O	O
to	O	O
exon	O	O
skipping	O	O
or	O	O
premature	O	O
protein	O	O
truncation	O	O
were	O	O
also	O	O
predominant	O	O
in	O	O
our	O	O
mutants	O	O
.	O	O

Six	O	O
different	O	O
mutations	O	O
were	O	O
identified	O	O
on	O	O
12	O	O
of	O	O
the	O	O
16	O	O
alleles	O	O
examined	O	O
.	O	O

Four	O	O
were	O	O
deletions	O	O
involving	O	O
a	O	O
loss	O	O
of	O	O
a	O	O
single	O	O
exon	O	O
exon	O	O
7	O	O
,	O	O
exon	O	O
16	O	O
,	O	O
exon	O	O
33	O	O
or	O	O
exon	O	O
35	O	O
.	O	O

The	O	O
others	O	O
were	O	O
minute	O	O
deletions	O	O
,	O	O
4649delA	O	O
in	O	O
exon	O	O
33	O	O
and	O	O
7883del5	O	O
in	O	O
exon	O	O
55	O	O
.	O	O

The	O	O
mutations	O	O
4612del165	O	O
and	O	O
7883del5	O	O
were	O	O
found	O	O
in	O	O
more	O	O
than	O	O
two	O	O
unrelated	O	O
families	O	O
;	O	O
44	O	O
%	O	O
(	O	O
7	O	O
of	O	O
16	O	O
)	O	O
of	O	O
the	O	O
mutant	O	O
alleles	O	O
had	O	O
one	O	O
of	O	O
the	O	O
two	O	O
mutations	O	O
.	O	O

The	O	O
4612del165	O	O
mutations	O	O
in	O	O
three	O	O
different	O	O
families	O	O
were	O	O
all	O	O
ascribed	O	O
to	O	O
the	O	O
same	O	O
T	O	O
-	O	O
-	O	O
>	O	O
A	O	O
substitution	O	O
at	O	O
the	O	O
splice	O	O
donor	O	O
site	O	O
in	O	O
intron	O	O
33	O	O
.	O	O

Microsatellite	O	O
genotyping	O	O
around	O	O
the	O	O
ATM	O	O
locus	O	O
also	O	O
indicated	O	O
that	O	O
a	O	O
common	O	O
haplotype	O	O
was	O	O
shared	O	O
by	O	O
the	O	O
mutant	O	O
alleles	O	O
in	O	O
both	O	O
mutations	O	O
.	O	O

This	O	O
suggests	O	O
that	O	O
these	O	O
two	O	O
founder	O	O
mutations	O	O
may	O	O
be	O	O
predominant	O	O
among	O	O
Japanese	O	O
ATM	O	O
mutant	O	O
alleles	O	O
.	O	O

Large	O	O
-	O	O
scale	O	O
RNA	O	O
differential	O	O
display	O	O
technology	O	O
applied	O	O
to	O	O
these	O	O
cell	O	O
lines	O	O
identified	O	O
several	O	O
differentially	O	O
expressed	O	O
genes	O	O
,	O	O
including	O	O
an	O	O
alpha	O	O
carbonic	O	O
anhydrase	O	O
gene	O	O
,	O	O
termed	O	O
CA12	O	O
.	O	O

The	O	O
deduced	O	O
protein	O	O
sequence	O	O
was	O	O
classified	O	O
as	O	O
a	O	O
one	O	O
-	O	O
pass	O	O
transmembrane	O	O
CA	O	O
possessing	O	O
an	O	O
apparently	O	O
intact	O	O
catalytic	O	O
domain	O	O
in	O	O
the	O	O
extracellular	O	O
CA	O	O
module	O	O
.	O	O

Similar	O	O
results	O	O
were	O	O
obtained	O	O
with	O	O
CA9	O	O
,	O	O
encoding	O	O
another	O	O
transmembrane	O	O
CA	O	O
with	O	O
an	O	O
intact	O	O
catalytic	O	O
domain	O	O
.	O	O

We	O	O
mapped	O	O
CA12	O	O
and	O	O
CA9	O	O
loci	O	O
to	O	O
chromosome	O	O
bands	O	O
15q22	O	O
and	O	O
17q21	O	O
.	O	O

In	O	O
previous	O	O
studies	O	O
,	O	O
we	O	O
have	O	O
found	O	O
two	O	O
common	O	O
mutations	O	O
in	O	O
Caucasians	O	O
and	O	O
Japanese	O	O
,	O	O
respectively	O	O
.	O	O

2	O	O
%	O	O
of	O	O
the	O	O
alleles	O	O
in	O	O
this	O	O
study	O	O
.	O	O

The	O	O
G301C	O	O
and	O	O
S162F	O	O
mutations	O	O
account	O	O
for	O	O
68	O	O
.	O	O

4	O	O
%	O	O
and	O	O
10	O	O
.	O	O

5	O	O
%	O	O
of	O	O
mutations	O	O
,	O	O
respectively	O	O
,	O	O
whereas	O	O
the	O	O
remaining	O	O
F69V	O	O
is	O	O
limited	O	O
to	O	O
a	O	O
single	O	O
allele	O	O
.	O	O

The	O	O
skewed	O	O
prevalence	O	O
of	O	O
G301C	O	O
in	O	O
only	O	O
Colombian	O	O
patients	O	O
and	O	O
haplotype	O	O
analysis	O	O
by	O	O
restriction	O	O
fragment	O	O
length	O	O
polymorphisms	O	O
in	O	O
the	O	O
GALNS	O	O
gene	O	O
suggest	O	O
that	O	O
G301C	O	O
originated	O	O
from	O	O
a	O	O
common	O	O
ancestor	O	O
.	O	O

Investigation	O	O
of	O	O
the	O	O
genetic	O	O
background	O	O
by	O	O
means	O	O
of	O	O
mtDNA	O	O
lineages	O	O
indicate	O	O
that	O	O
all	O	O
our	O	O
patients	O	O
are	O	O
probably	O	O
of	O	O
native	O	O
American	O	O
descent	O	O
W474C	O	O
amino	O	O
acid	O	O
substitution	O	O
affects	O	O
early	O	O
processing	O	O
of	O	O
the	O	O
alpha	O	O
-	O	O
subunit	O	O
of	O	O
beta	O	O
-	O	O
hexosaminidase	O	O
A	O	O
and	O	O
is	O	O
associated	O	O
with	O	O
subacute	O	O
G	B-Disease	D020143
(	I-Disease	D020143
M2	I-Disease	D020143
)	I-Disease	D020143
gangliosidosis	I-Disease	D020143
.	O	O

Less	O	O
severe	O	O
,	O	O
subacute	O	O
(	O	O
juvenile	O	O
-	O	O
onset	O	O
)	O	O
and	O	O
chronic	O	O
(	O	O
adult	O	O
-	O	O
onset	O	O
)	O	O
variants	O	O
are	O	O
characterized	O	O
by	O	O
a	O	O
broad	O	O
spectrum	O	O
of	O	O
clinical	O	O
manifestations	O	O
and	O	O
are	O	O
associated	O	O
with	O	O
residual	O	O
levels	O	O
of	O	O
Hex	O	O
A	O	O
enzyme	O	O
activity	O	O
.	O	O

We	O	O
identified	O	O
a	O	O
1422	O	O
G	O	O
-	O	O
-	O	O
>	O	O
C	O	O
(	O	O
amino	O	O
acid	O	O
W474C	O	O
)	O	O
substitution	O	O
in	O	O
the	O	O
first	O	O
position	O	O
of	O	O
exon	O	O
13	O	O
of	O	O
HEXA	O	O
of	O	O
a	O	O
non	O	O
-	O	O
Jewish	O	O
proband	O	O
who	O	O
manifested	O	O
a	O	O
subacute	O	O
variant	O	O
of	O	O
G	B-Disease	D020143
(	I-Disease	D020143
M2	I-Disease	D020143
)	I-Disease	D020143
gangliosidosis	I-Disease	D020143
.	O	O

On	O	O
the	O	O
second	O	O
maternally	O	O
inherited	O	O
allele	O	O
,	O	O
we	O	O
identified	O	O
the	O	O
common	O	O
infantile	O	O
disease	O	O
-	O	O
causing	O	O
4	O	O
-	O	O
bp	O	O
insertion	O	O
,	O	O
+	O	O
TATC	O	O
1278	O	O
,	O	O
in	O	O
exon	O	O
11	O	O
.	O	O

Pulse	O	O
-	O	O
chase	O	O
analysis	O	O
using	O	O
proband	O	O
fibroblasts	O	O
revealed	O	O
that	O	O
the	O	O
W474C	O	O
-	O	O
containing	O	O
alpha	O	O
-	O	O
subunit	O	O
precursor	O	O
was	O	O
normally	O	O
synthesized	O	O
,	O	O
but	O	O
not	O	O
phosphorylated	O	O
or	O	O
secreted	O	O
,	O	O
and	O	O
the	O	O
mature	O	O
lysosomal	O	O
alpha	O	O
-	O	O
subunit	O	O
was	O	O
not	O	O
detected	O	O
.	O	O

Furthermore	O	O
,	O	O
the	O	O
precursor	O	O
level	O	O
of	O	O
the	O	O
W474C	O	O
alpha	O	O
-	O	O
subunit	O	O
was	O	O
found	O	O
to	O	O
accumulate	O	O
in	O	O
comparison	O	O
to	O	O
the	O	O
normal	O	O
alpha	O	O
-	O	O
subunit	O	O
precursor	O	O
levels	O	O
.	O	O

.	O	O

To	O	O
obtain	O	O
clues	O	O
to	O	O
the	O	O
normal	O	O
biological	O	O
role	O	O
of	O	O
DMPK	O	O
in	O	O
cellular	O	O
ion	O	O
homeostasis	O	O
,	O	O
we	O	O
have	O	O
compared	O	O
the	O	O
resting	O	O
[	O	O
Ca2	O	O
+	O	O
]	O	O
i	O	O
,	O	O
the	O	O
amplitude	O	O
and	O	O
shape	O	O
of	O	O
depolarization	O	O
-	O	O
induced	O	O
Ca2	O	O
+	O	O
transients	O	O
,	O	O
and	O	O
the	O	O
content	O	O
of	O	O
ATP	O	O
-	O	O
driven	O	O
ion	O	O
pumps	O	O
in	O	O
cultured	O	O
skeletal	O	O
muscle	O	O
cells	O	O
of	O	O
wild	O	O
-	O	O
type	O	O
and	O	O
DMPK	O	O
[	O	O
-	O	O
/	O	O
-	O	O
]	O	O
knockout	O	O
mice	O	O
.	O	O

In	O	O
vitro	O	O
-	O	O
differentiated	O	O
DMPK	O	O
[	O	O
-	O	O
/	O	O
-	O	O
]	O	O
myotubes	O	O
exhibit	O	O
a	O	O
higher	O	O
resting	O	O
[	O	O
Ca2	O	O
+	O	O
]	O	O
i	O	O
than	O	O
do	O	O
wild	O	O
-	O	O
type	O	O
myotubes	O	O
because	O	O
of	O	O
an	O	O
altered	O	O
open	O	O
probability	O	O
of	O	O
voltage	O	O
-	O	O
dependent	O	O
l	O	O
-	O	O
type	O	O
Ca2	O	O
+	O	O
and	O	O
Na	O	O
+	O	O
channels	O	O
.	O	O

The	O	O
mutant	O	O
myotubes	O	O
exhibit	O	O
smaller	O	O
and	O	O
slower	O	O
Ca2	O	O
+	O	O
responses	O	O
upon	O	O
triggering	O	O
by	O	O
acetylcholine	O	O
or	O	O
high	O	O
external	O	O
K	O	O
+	O	O
.	O	O

In	O	O
addition	O	O
,	O	O
we	O	O
observed	O	O
that	O	O
these	O	O
Ca2	O	O
+	O	O
transients	O	O
partially	O	O
result	O	O
from	O	O
an	O	O
influx	O	O
of	O	O
extracellular	O	O
Ca2	O	O
+	O	O
through	O	O
the	O	O
l	O	O
-	O	O
type	O	O
Ca2	O	O
+	O	O
channel	O	O
.	O	O

Neither	O	O
the	O	O
content	O	O
nor	O	O
the	O	O
activity	O	O
of	O	O
Na	O	O
+	O	O
/	O	O
K	O	O
+	O	O
ATPase	O	O
and	O	O
sarcoplasmic	O	O
reticulum	O	O
Ca2	O	O
+	O	O
-	O	O
ATPase	O	O
are	O	O
affected	O	O
by	O	O
DMPK	O	O
absence	O	O
.	O	O

In	O	O
conclusion	O	O
,	O	O
our	O	O
data	O	O
suggest	O	O
that	O	O
DMPK	O	O
is	O	O
involved	O	O
in	O	O
modulating	O	O
the	O	O
initial	O	O
events	O	O
of	O	O
excitation	O	O
-	O	O
contraction	O	O
coupling	O	O
in	O	O
skeletal	O	O
muscle	O	O
.	O	O

.	O	O

The	O	O
insertion	O	O
was	O	O
a	O	O
5	O	O
-	O	O
truncated	O	O
form	O	O
of	O	O
human	O	O
L1	O	O
inversely	O	O
integrated	O	O
in	O	O
the	O	O
5	O	O
-	O	O
untranslated	O	O
region	O	O
in	O	O
the	O	O
muscle	O	O
exon	O	O
1	O	O
,	O	O
which	O	O
affected	O	O
the	O	O
transcription	O	O
or	O	O
the	O	O
stability	O	O
of	O	O
the	O	O
muscle	O	O
form	O	O
of	O	O
dystrophin	O	O
transcripts	O	O
but	O	O
not	O	O
that	O	O
of	O	O
the	O	O
brain	O	O
or	O	O
Purkinje	O	O
cell	O	O
form	O	O
,	O	O
probably	O	O
due	O	O
to	O	O
its	O	O
unique	O	O
site	O	O
of	O	O
integration	O	O
.	O	O

.	O	O

Genetic	O	O
heterogeneity	O	O
of	O	O
Saethre	B-Disease	OMIM:101400
-	I-Disease	OMIM:101400
Chotzen	I-Disease	OMIM:101400
syndrome	I-Disease	OMIM:101400
,	O	O
due	O	O
to	O	O
TWIST	O	O
and	O	O
FGFR	O	O
mutations	O	O
.	O	O

Nine	O	O
novel	O	O
and	O	O
three	O	O
recurrent	O	O
TWIST	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
12	O	O
families	O	O
.	O	O

Seven	O	O
families	O	O
were	O	O
found	O	O
to	O	O
have	O	O
the	O	O
FGFR3	O	O
P250R	O	O
mutation	O	O
,	O	O
and	O	O
one	O	O
individual	O	O
was	O	O
found	O	O
to	O	O
have	O	O
an	O	O
FGFR2	O	O
VV269	O	O
-	O	O
270	O	O
deletion	O	O
.	O	O

To	O	O
date	O	O
,	O	O
our	O	O
detection	O	O
rate	O	O
for	O	O
TWIST	O	O
or	O	O
FGFR	O	O
mutations	O	O
is	O	O
68	O	O
%	O	O
in	O	O
our	O	O
Saethre	B-Disease	OMIM:101400
-	I-Disease	OMIM:101400
Chotzen	I-Disease	OMIM:101400
syndrome	I-Disease	OMIM:101400
patients	O	O
,	O	O
including	O	O
our	O	O
five	O	O
patients	O	O
elsewhere	O	O
reported	O	O
with	O	O
TWIST	O	O
mutations	O	O
.	O	O

More	O	O
than	O	O
35	O	O
different	O	O
TWIST	O	O
mutations	O	O
are	O	O
now	O	O
known	O	O
in	O	O
the	O	O
literature	O	O
.	O	O

Significant	O	O
intra	O	O
-	O	O
and	O	O
interfamilial	O	O
phenotypic	O	O
variability	O	O
is	O	O
present	O	O
for	O	O
either	O	O
TWIST	O	O
mutations	O	O
or	O	O
FGFR	O	O
mutations	O	O
.	O	O

The	O	O
overlap	O	O
in	O	O
clinical	O	O
features	O	O
and	O	O
the	O	O
presence	O	O
,	O	O
in	O	O
the	O	O
same	O	O
genes	O	O
,	O	O
of	O	O
mutations	O	O
for	O	O
more	O	O
than	O	O
one	O	O
craniosynostotic	B-Disease	D003398
condition	I-Disease	D003398
-	O	O
such	O	O
as	O	O
Saethre	B-Disease	OMIM:101400
-	I-Disease	OMIM:101400
Chotzen	I-Disease	OMIM:101400
,	I-Disease	OMIM:101400
Crouzon	I-Disease	OMIM:101400
,	I-Disease	OMIM:101400
and	I-Disease	OMIM:101400
Pfeiffer	I-Disease	OMIM:101400
syndromes	I-Disease	OMIM:101400
-	O	O
support	O	O
the	O	O
hypothesis	O	O
that	O	O
TWIST	O	O
and	O	O
FGFRs	O	O
are	O	O
components	O	O
of	O	O
the	O	O
same	O	O
molecular	O	O
pathway	O	O
involved	O	O
in	O	O
the	O	O
modulation	O	O
of	O	O
craniofacial	O	O
and	O	O
limb	O	O
development	O	O
in	O	O
humans	O	O
.	O	O

.	O	O

Deletion	O	O
mapping	O	O
studies	O	O
have	O	O
unambiguously	O	O
identified	O	O
a	O	O
region	O	O
of	O	O
chromosome	O	O
10q23	O	O
to	O	O
be	O	O
the	O	O
minimal	O	O
area	O	O
of	O	O
loss	O	O
.	O	O

We	O	O
then	O	O
proceeded	O	O
with	O	O
sequence	O	O
analysis	O	O
of	O	O
the	O	O
entire	O	O
PTEN	O	O
/	O	O
MMAC1	O	O
coding	O	O
region	O	O
and	O	O
tested	O	O
for	O	O
homozygous	O	O
deletion	O	O
with	O	O
new	O	O
intragenic	O	O
markers	O	O
in	O	O
these	O	O
23	O	O
cases	O	O
with	O	O
10q23	O	O
loss	O	O
of	O	O
heterozygosity	O	O
.	O	O

.	O	O

We	O	O
found	O	O
two	O	O
common	O	O
mutations	O	O
that	O	O
together	O	O
accounted	O	O
for	O	O
32	O	O
%	O	O
of	O	O
the	O	O
44	O	O
unrelated	O	O
alleles	O	O
in	O	O
these	O	O
patients	O	O
.	O	O

One	O	O
is	O	O
the	O	O
T312S	O	O
mutation	O	O
,	O	O
a	O	O
novel	O	O
mutation	O	O
found	O	O
exclusively	O	O
in	O	O
milder	O	O
patients	O	O
.	O	O

The	O	O
other	O	O
is	O	O
the	O	O
previously	O	O
described	O	O
I113F	O	O
that	O	O
produces	O	O
a	O	O
severe	O	O
phenotype	O	O
.	O	O

The	O	O
I113F	O	O
and	O	O
T312S	O	O
mutations	O	O
accounted	O	O
for	O	O
8	O	O
(	O	O
18	O	O
%	O	O
)	O	O
and	O	O
6	O	O
(	O	O
14	O	O
%	O	O
)	O	O
of	O	O
44	O	O
unrelated	O	O
alleles	O	O
,	O	O
respectively	O	O
.	O	O

The	O	O
relatively	O	O
high	O	O
residual	O	O
GALNS	O	O
activity	O	O
seen	O	O
when	O	O
the	O	O
T312S	O	O
mutant	O	O
cDNA	O	O
is	O	O
overexpressed	O	O
in	O	O
mutant	O	O
cells	O	O
provides	O	O
an	O	O
explanation	O	O
for	O	O
the	O	O
mild	O	O
phenotype	O	O
in	O	O
patients	O	O
with	O	O
this	O	O
mutation	O	O
.	O	O

The	O	O
distribution	O	O
and	O	O
relative	O	O
frequencies	O	O
of	O	O
the	O	O
I113F	O	O
and	O	O
T312S	O	O
mutations	O	O
in	O	O
Australia	O	O
corresponded	O	O
to	O	O
those	O	O
observed	O	O
in	O	O
Northern	O	O
Ireland	O	O
and	O	O
are	O	O
unique	O	O
to	O	O
these	O	O
two	O	O
populations	O	O
,	O	O
suggesting	O	O
that	O	O
both	O	O
mutations	O	O
were	O	O
probably	O	O
introduced	O	O
to	O	O
Australia	O	O
by	O	O
Irish	O	O
migrants	O	O
during	O	O
the	O	O
19th	O	O
century	O	O
.	O	O

Haplotype	O	O
analysis	O	O
using	O	O
6	O	O
RFLPs	O	O
provides	O	O
additional	O	O
data	O	O
that	O	O
the	O	O
I113F	O	O
mutation	O	O
originated	O	O
from	O	O
a	O	O
common	O	O
ancestor	O	O
.	O	O

The	O	O
other	O	O
9	O	O
novel	O	O
mutations	O	O
identified	O	O
in	O	O
these	O	O
23	O	O
patients	O	O
were	O	O
each	O	O
limited	O	O
to	O	O
a	O	O
single	O	O
family	O	O
.	O	O

.	O	O

The	O	O
results	O	O
suggest	O	O
that	O	O
a	O	O
few	O	O
common	O	O
ancestral	O	O
mutations	O	O
in	O	O
both	O	O
Caucasian	O	O
and	O	O
Japanese	O	O
populations	O	O
have	O	O
originated	O	O
by	O	O
expansion	O	O
of	O	O
an	O	O
ancestral	O	O
n	O	O
=	O	O
5	O	O
repeat	O	O
to	O	O
n	O	O
=	O	O
19	O	O
-	O	O
37	O	O
copies	O	O
.	O	O

.	O	O

Sixteen	O	O
different	O	O
p16	O	O
germline	O	O
mutations	O	O
were	O	O
found	O	O
in	O	O
21	O	O
families	O	O
,	O	O
while	O	O
one	O	O
germline	O	O
mutation	O	O
,	O	O
Arg24His	O	O
,	O	O
was	O	O
detected	O	O
in	O	O
the	O	O
CDK4	O	O
gene	O	O
.	O	O

The	O	O
frequency	O	O
of	O	O
p16	O	O
gene	O	O
mutation	O	O
in	O	O
our	O	O
sample	O	O
(	O	O
44	O	O
%	O	O
)	O	O
is	O	O
among	O	O
the	O	O
highest	O	O
rates	O	O
yet	O	O
reported	O	O
and	O	O
the	O	O
CDK4	O	O
mutation	O	O
is	O	O
the	O	O
second	O	O
mutation	O	O
detected	O	O
in	O	O
this	O	O
gene	O	O
worldwide	O	O
.	O	O

.	O	O

Hereditary	B-Disease	D046349
coproporphyria	I-Disease	D046349
(	O	O
HC	B-Disease	D046349
)	O	O
is	O	O
an	O	O
acute	O	O
hepatic	B-Disease	D017094
porphyria	I-Disease	D017094
with	O	O
autosomal	O	O
dominant	O	O
inheritance	O	O
caused	O	O
by	O	O
deficient	B-Disease	D046349
activity	I-Disease	D046349
of	I-Disease	D046349
coproporphyrinogen	I-Disease	D046349
III	I-Disease	D046349
oxidase	I-Disease	D046349
(	O	O
CPO	O	O
)	O	O
.	O	O

Skin	O	O
photosensitivity	O	O
may	O	O
also	O	O
be	O	O
present	O	O
.	O	O

The	O	O
seven	O	O
exons	O	O
,	O	O
the	O	O
exon	O	O
/	O	O
intron	O	O
boundaries	O	O
and	O	O
part	O	O
of	O	O
3	O	O
noncoding	O	O
sequence	O	O
of	O	O
the	O	O
CPO	O	O
gene	O	O
were	O	O
systematically	O	O
analyzed	O	O
by	O	O
an	O	O
exon	O	O
-	O	O
by	O	O
-	O	O
exon	O	O
denaturing	O	O
gradient	O	O
gel	O	O
electrophoresis	O	O
(	O	O
DGGE	O	O
)	O	O
strategy	O	O
followed	O	O
by	O	O
direct	O	O
sequencing	O	O
in	O	O
seven	O	O
unrelated	O	O
heterozygous	O	O
HC	B-Disease	D046349
patients	O	O
from	O	O
France	O	O
,	O	O
Holland	O	O
,	O	O
and	O	O
Czech	O	O
Republic	O	O
.	O	O

Seven	O	O
novel	O	O
mutations	O	O
and	O	O
two	O	O
new	O	O
polymorphisms	O	O
were	O	O
detected	O	O
.	O	O

Among	O	O
these	O	O
mutations	O	O
two	O	O
are	O	O
missense	O	O
(	O	O
G197W	O	O
,	O	O
W427R	O	O
)	O	O
,	O	O
two	O	O
are	O	O
nonsense	O	O
(	O	O
Q306X	O	O
,	O	O
Q385X	O	O
)	O	O
,	O	O
two	O	O
are	O	O
small	O	O
deletions	O	O
(	O	O
662de14bp	O	O
;	O	O
1168del3bp	O	O
removing	O	O
a	O	O
glycine	O	O
at	O	O
position	O	O
390	O	O
)	O	O
,	O	O
and	O	O
one	O	O
is	O	O
a	O	O
splicing	O	O
mutation	O	O
(	O	O
IVS1	O	O
-	O	O
15c	O	O
-	O	O
-	O	O
>	O	O
g	O	O
)	O	O
which	O	O
creates	O	O
a	O	O
new	O	O
acceptor	O	O
splice	O	O
site	O	O
.	O	O

The	O	O
pathological	O	O
significance	O	O
of	O	O
the	O	O
point	O	O
mutations	O	O
G197W	O	O
,	O	O
W427R	O	O
,	O	O
and	O	O
the	O	O
in	O	O
-	O	O
frame	O	O
deletion	O	O
390delGly	O	O
were	O	O
assessed	O	O
by	O	O
their	O	O
respective	O	O
expression	O	O
in	O	O
a	O	O
prokaryotic	O	O
system	O	O
using	O	O
site	O	O
-	O	O
directed	O	O
mutagenesis	O	O
.	O	O

These	O	O
mutations	O	O
resulted	O	O
in	O	O
the	O	O
absence	O	O
or	O	O
a	O	O
dramatic	O	O
decrease	O	O
of	O	O
CPO	O	O
activity	O	O
.	O	O

The	O	O
two	O	O
polymorphisms	O	O
were	O	O
localized	O	O
in	O	O
noncoding	O	O
part	O	O
of	O	O
the	O	O
gene	O	O
1	O	O
)	O	O
a	O	O
C	O	O
/	O	O
G	O	O
polymorphism	O	O
in	O	O
the	O	O
promotor	O	O
region	O	O
,	O	O
142	O	O
bp	O	O
upstream	O	O
from	O	O
the	O	O
transcriptional	O	O
initiation	O	O
site	O	O
(	O	O
-	O	O
142C	O	O
/	O	O
G	O	O
)	O	O
,	O	O
and	O	O
2	O	O
)	O	O
a	O	O
6	O	O
bp	O	O
deletion	O	O
polymorphism	O	O
in	O	O
the	O	O
3	O	O
noncoding	O	O
part	O	O
of	O	O
the	O	O
CPO	O	O
gene	O	O
,	O	O
574	O	O
bp	O	O
downstream	O	O
of	O	O
the	O	O
last	O	O
base	O	O
of	O	O
the	O	O
normal	O	O
termination	O	O
codon	O	O
(	O	O
+	O	O
574	O	O
delATTCTT	O	O
)	O	O
.	O	O

.	O	O

The	O	O
Hp	O	O
gene	O	O
cluster	O	O
consists	O	O
of	O	O
coding	O	O
regions	O	O
of	O	O
the	O	O
alpha	O	O
chain	O	O
and	O	O
beta	O	O
chain	O	O
of	O	O
the	O	O
haptoglobin	O	O
gene	O	O
(	O	O
Hp	O	O
)	O	O
and	O	O
of	O	O
the	O	O
alpha	O	O
chain	O	O
and	O	O
beta	O	O
chain	O	O
of	O	O
the	O	O
haptoglobin	O	O
-	O	O
related	O	O
gene	O	O
(	O	O
Hpr	O	O
)	O	O
,	O	O
in	O	O
tandem	O	O
from	O	O
the	O	O
5	O	O
side	O	O
.	O	O

The	O	O
Hp2	O	O
/	O	O
Hpdel	O	O
individuals	O	O
had	O	O
an	O	O
extremely	O	O
low	O	O
level	O	O
of	O	O
Hp	O	O
(	O	O
mean	O	O
+	O	O
/	O	O
-	O	O
SD	O	O
=	O	O
0	O	O
.	O	O

049	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

043	O	O
mg	O	O
/	O	O
ml	O	O
;	O	O
n	O	O
=	O	O
6	O	O
)	O	O
,	O	O
compared	O	O
with	O	O
the	O	O
level	O	O
(	O	O
1	O	O
.	O	O

64	O	O
+	O	O
/	O	O
-	O	O
1	O	O
.	O	O

07	O	O
mg	O	O
/	O	O
ml	O	O
)	O	O
obtained	O	O
from	O	O
52	O	O
healthy	O	O
volunteers	O	O
having	O	O
phenotype	O	O
Hp2	O	O
,	O	O
whereas	O	O
the	O	O
serum	O	O
Hp	O	O
level	O	O
of	O	O
an	O	O
individual	O	O
with	O	O
Hp1	O	O
/	O	O
Hpdel	O	O
was	O	O
0	O	O
.	O	O

50	O	O
mg	O	O
/	O	O
ml	O	O
,	O	O
which	O	O
was	O	O
approximately	O	O
half	O	O
the	O	O
level	O	O
of	O	O
Hp	O	O
in	O	O
control	O	O
sera	O	O
from	O	O
the	O	O
Hp1	O	O
phenotype	O	O
(	O	O
1	O	O
.	O	O

26	O	O
+	O	O
/	O	O
-	O	O
0	O	O
.	O	O

33	O	O
mg	O	O
/	O	O
ml	O	O
;	O	O
n	O	O
=	O	O
9	O	O
)	O	O
,	O	O
showing	O	O
a	O	O
gene	O	O
-	O	O
dosage	O	O
effect	O	O
.	O	O

The	O	O
other	O	O
allele	O	O
(	O	O
Hp2	O	O
)	O	O
of	O	O
individuals	O	O
with	O	O
Hp2	O	O
/	O	O
Hpdel	O	O
was	O	O
found	O	O
to	O	O
have	O	O
,	O	O
in	O	O
all	O	O
exons	O	O
,	O	O
no	O	O
mutation	O	O
,	O	O
by	O	O
DNA	O	O
sequencing	O	O
.	O	O

No	O	O
desmoid	B-Disease	D018222
tumors	I-Disease	D018222
were	O	O
found	O	O
in	O	O
these	O	O
kindreds	O	O
.	O	O

.	O	O

Three	O	O
patients	O	O
with	O	O
the	O	O
I1307K	O	O
allele	O	O
were	O	O
detected	O	O
,	O	O
each	O	O
of	O	O
Ashkenazi	O	O
descent	O	O
.	O	O

.	O	O

The	O	O
present	O	O
study	O	O
used	O	O
PCR	O	O
and	O	O
restriction	O	O
-	O	O
enzyme	O	O
digestion	O	O
to	O	O
analyze	O	O
the	O	O
frequency	O	O
of	O	O
the	O	O
845	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
and	O	O
187	O	O
C	O	O
-	O	O
-	O	O
>	O	O
G	O	O
mutations	O	O
in	O	O
HLA	O	O
-	O	O
typed	O	O
samples	O	O
from	O	O
non	O	O
-	O	O
Caucasian	O	O
populations	O	O
,	O	O
comprising	O	O
Australian	O	O
Aboriginal	O	O
,	O	O
Chinese	O	O
,	O	O
and	O	O
Pacific	O	O
Islanders	O	O
.	O	O

Results	O	O
showed	O	O
that	O	O
the	O	O
845	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
mutation	O	O
was	O	O
present	O	O
in	O	O
these	O	O
populations	O	O
(	O	O
allele	O	O
frequency	O	O
0	O	O
.	O	O

32	O	O
%	O	O
)	O	O
,	O	O
and	O	O
,	O	O
furthermore	O	O
,	O	O
it	O	O
was	O	O
always	O	O
seen	O	O
in	O	O
conjunction	O	O
with	O	O
HLA	O	O
haplotypes	O	O
common	O	O
in	O	O
Caucasians	O	O
,	O	O
suggesting	O	O
that	O	O
845	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
may	O	O
have	O	O
been	O	O
introduced	O	O
into	O	O
these	O	O
populations	O	O
by	O	O
Caucasian	O	O
admixture	O	O
.	O	O

187	O	O
C	O	O
-	O	O
-	O	O
>	O	O
G	O	O
was	O	O
present	O	O
at	O	O
an	O	O
allele	O	O
frequency	O	O
of	O	O
2	O	O
.	O	O

68	O	O
%	O	O
in	O	O
the	O	O
two	O	O
populations	O	O
analyzed	O	O
(	O	O
Australian	O	O
Aboriginal	O	O
and	O	O
Chinese	O	O
)	O	O
.	O	O

In	O	O
the	O	O
Australian	O	O
Aboriginal	O	O
samples	O	O
,	O	O
187	O	O
C	O	O
-	O	O
-	O	O
>	O	O
G	O	O
was	O	O
found	O	O
to	O	O
be	O	O
associated	O	O
with	O	O
HLA	O	O
haplotypes	O	O
common	O	O
in	O	O
Caucasians	O	O
,	O	O
suggesting	O	O
that	O	O
it	O	O
was	O	O
introduced	O	O
by	O	O
recent	O	O
admixture	O	O
.	O	O

In	O	O
the	O	O
Chinese	O	O
samples	O	O
analyzed	O	O
,	O	O
187	O	O
C	O	O
-	O	O
-	O	O
>	O	O
G	O	O
was	O	O
present	O	O
in	O	O
association	O	O
with	O	O
a	O	O
wide	O	O
variety	O	O
of	O	O
HLA	O	O
haplotypes	O	O
,	O	O
showing	O	O
this	O	O
mutation	O	O
to	O	O
be	O	O
widespread	O	O
and	O	O
likely	O	O
to	O	O
predate	O	O
the	O	O
more	O	O
genetically	O	O
restricted	O	O
845	O	O
G	O	O
-	O	O
-	O	O
>	O	O
A	O	O
mutation	O	O
.	O	O

BRCA1	O	O
required	O	O
for	O	O
transcription	O	O
-	O	O
coupled	O	O
repair	O	O
of	O	O
oxidative	O	O
DNA	O	O
damage	O	O
.	O	O

Association	O	O
of	O	O
the	O	O
BRCA1	O	O
protein	O	O
with	O	O
the	O	O
DNA	O	O
repair	O	O
protein	O	O
Rad51	O	O
and	O	O
changes	O	O
in	O	O
the	O	O
phosphorylation	O	O
and	O	O
cellular	O	O
localization	O	O
of	O	O
the	O	O
protein	O	O
after	O	O
exposure	O	O
to	O	O
DNA	O	O
-	O	O
damaging	O	O
agents	O	O
are	O	O
consistent	O	O
with	O	O
a	O	O
role	O	O
for	O	O
BRCA1	O	O
in	O	O
DNA	O	O
repair	O	O
.	O	O

These	O	O
results	O	O
suggest	O	O
that	O	O
BRCA1	O	O
participates	O	O
,	O	O
directly	O	O
or	O	O
indirectly	O	O
,	O	O
in	O	O
transcription	O	O
-	O	O
coupled	O	O
repair	O	O
of	O	O
oxidative	O	O
DNA	O	O
damage	O	O
.	O	O

.	O	O

We	O	O
generated	O	O
a	O	O
mouse	O	O
model	O	O
for	O	O
this	O	O
disease	O	O
by	O	O
using	O	O
gene	O	O
targeting	O	O
.	O	O

vWf	B-Disease	C531844
-	I-Disease	C531844
deficient	I-Disease	C531844
mice	O	O
appeared	O	O
normal	O	O
at	O	O
birth	O	O
;	O	O
they	O	O
were	O	O
viable	O	O
and	O	O
fertile	O	O
.	O	O

The	O	O
mutant	O	O
mice	O	O
exhibited	O	O
defects	O	O
in	O	O
hemostasis	O	O
with	O	O
a	O	O
highly	O	O
prolonged	O	O
bleeding	O	O
time	O	O
and	O	O
spontaneous	O	O
bleeding	O	O
events	O	O
in	O	O
approximately	O	O
10	O	O
%	O	O
of	O	O
neonates	O	O
.	O	O

As	O	O
in	O	O
the	O	O
human	O	O
disease	O	O
,	O	O
the	O	O
factor	O	O
VIII	O	O
level	O	O
in	O	O
these	O	O
mice	O	O
was	O	O
reduced	O	O
strongly	O	O
as	O	O
a	O	O
result	O	O
of	O	O
the	O	O
lack	O	O
of	O	O
protection	O	O
provided	O	O
by	O	O
vWf	O	O
.	O	O

In	O	O
this	O	O
model	O	O
,	O	O
the	O	O
exteriorized	O	O
mesentery	O	O
was	O	O
superfused	O	O
with	O	O
ferric	O	O
chloride	O	O
and	O	O
the	O	O
accumulation	O	O
of	O	O
fluorescently	O	O
labeled	O	O
platelets	O	O
was	O	O
observed	O	O
by	O	O
intravital	O	O
microscopy	O	O
.	O	O

.	O	O

Remarkably	O	O
,	O	O
this	O	O
occurs	O	O
without	O	O
affecting	O	O
the	O	O
growth	O	O
rate	O	O
and	O	O
cell	O	O
cycle	O	O
profile	O	O
of	O	O
these	O	O
cells	O	O
in	O	O
culture	O	O
.	O	O

.	O	O

An	O	O
allele	O	O
-	O	O
specific	O	O
polymerase	O	O
chain	O	O
reaction	O	O
system	O	O
designed	O	O
to	O	O
detect	O	O
exclusively	O	O
only	O	O
one	O	O
of	O	O
the	O	O
normal	O	O
and	O	O
mutant	O	O
alleles	O	O
indicated	O	O
that	O	O
all	O	O
the	O	O
four	O	O
patients	O	O
were	O	O
homozygous	O	O
for	O	O
the	O	O
mutation	O	O
in	O	O
exon	O	O
4	O	O
and	O	O
that	O	O
the	O	O
parents	O	O
of	O	O
patient	O	O
2	O	O
were	O	O
heterozygous	O	O
.	O	O

.	O	O

Human	B-Disease	OMIM:609814
complement	I-Disease	OMIM:609814
factor	I-Disease	OMIM:609814
H	I-Disease	OMIM:609814
deficiency	I-Disease	OMIM:609814
associated	O	O
with	O	O
hemolytic	B-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
.	O	O

Five	O	O
of	O	O
the	O	O
cases	O	O
were	O	O
observed	O	O
in	O	O
children	O	O
presenting	O	O
with	O	O
idiopathic	O	O
hemolytic	B-Disease	D006463
uremic	I-Disease	D006463
syndrome	I-Disease	D006463
(	O	O
HUS	B-Disease	D006463
)	O	O
.	O	O

Two	O	O
of	O	O
the	O	O
children	O	O
exhibited	O	O
a	O	O
homozygous	O	O
deficiency	O	O
characterized	O	O
by	O	O
the	O	O
absence	O	O
of	O	O
the	O	O
150	O	O
-	O	O
kD	O	O
form	O	O
of	O	O
Factor	O	O
H	O	O
and	O	O
the	O	O
presence	O	O
,	O	O
upon	O	O
immunoblotting	O	O
,	O	O
of	O	O
the	O	O
42	O	O
-	O	O
kD	O	O
Factor	O	O
H	O	O
-	O	O
like	O	O
protein	O	O
1	O	O
(	O	O
FHL	O	O
-	O	O
1	O	O
)	O	O
and	O	O
other	O	O
FH	O	O
-	O	O
related	O	O
protein	O	O
(	O	O
FHR	O	O
)	O	O
bands	O	O
.	O	O

Southern	O	O
blot	O	O
and	O	O
PCR	O	O
analysis	O	O
of	O	O
DNA	O	O
of	O	O
one	O	O
patient	O	O
with	O	O
homozygous	O	O
deficiency	O	O
ruled	O	O
out	O	O
the	O	O
presence	O	O
of	O	O
a	O	O
large	O	O
deletion	O	O
of	O	O
the	O	O
FH	O	O
gene	O	O
as	O	O
the	O	O
underlying	O	O
defect	O	O
for	O	O
the	O	O
deficiency	O	O
.	O	O

The	O	O
other	O	O
four	O	O
children	O	O
presented	O	O
with	O	O
heterozygous	O	O
deficiency	O	O
and	O	O
exhibited	O	O
a	O	O
normal	O	O
immunoblotting	O	O
pattern	O	O
of	O	O
proteins	O	O
of	O	O
the	O	O
FH	O	O
family	O	O
.	O	O

These	O	O
observations	O	O
suggest	O	O
a	O	O
role	O	O
for	O	O
FH	O	O
and	O	O
/	O	O
or	O	O
FH	O	O
receptors	O	O
in	O	O
the	O	O
pathogenesis	O	O
of	O	O
idiopathic	O	O
HUS	B-Disease	D006463
.	O	O

.	O	O

Cell	O	O
cycle	O	O
-	O	O
dependent	O	O
colocalization	O	O
of	O	O
BARD1	O	O
and	O	O
BRCA1	O	O
proteins	O	O
in	O	O
discrete	O	O
nuclear	O	O
domains	O	O
.	O	O

Although	O	O
the	O	O
biochemical	O	O
properties	O	O
of	O	O
BRCA1	O	O
polypeptides	O	O
are	O	O
not	O	O
understood	O	O
,	O	O
their	O	O
expression	O	O
pattern	O	O
and	O	O
subcellular	O	O
localization	O	O
suggest	O	O
a	O	O
role	O	O
in	O	O
cell	O	O
-	O	O
cycle	O	O
regulation	O	O
.	O	O

When	O	O
resting	O	O
cells	O	O
are	O	O
induced	O	O
to	O	O
proliferate	O	O
,	O	O
the	O	O
steady	O	O
-	O	O
state	O	O
levels	O	O
of	O	O
BRCA1	O	O
increase	O	O
in	O	O
late	O	O
G1	O	O
and	O	O
reach	O	O
a	O	O
maximum	O	O
during	O	O
S	O	O
phase	O	O
.	O	O

Moreover	O	O
,	O	O
in	O	O
S	O	O
phase	O	O
cells	O	O
,	O	O
BRCA1	O	O
polypeptides	O	O
are	O	O
hyperphosphorylated	O	O
and	O	O
accumulate	O	O
into	O	O
discrete	O	O
subnuclear	O	O
foci	O	O
termed	O	O
"	O	O
BRCA1	O	O
nuclear	O	O
dots	O	O
.	O	O

"	O	O
BRCA1	O	O
associates	O	O
in	O	O
vivo	O	O
with	O	O
a	O	O
structurally	O	O
related	O	O
protein	O	O
termed	O	O
BARD1	O	O
.	O	O

Here	O	O
we	O	O
show	O	O
that	O	O
the	O	O
steady	O	O
-	O	O
state	O	O
levels	O	O
of	O	O
BARD1	O	O
,	O	O
unlike	O	O
those	O	O
of	O	O
BRCA1	O	O
,	O	O
remain	O	O
relatively	O	O
constant	O	O
during	O	O
cell	O	O
cycle	O	O
progression	O	O
.	O	O

However	O	O
,	O	O
immunostaining	O	O
revealed	O	O
that	O	O
BARD1	O	O
resides	O	O
within	O	O
BRCA1	O	O
nuclear	O	O
dots	O	O
during	O	O
S	O	O
phase	O	O
of	O	O
the	O	O
cell	O	O
cycle	O	O
,	O	O
but	O	O
not	O	O
during	O	O
the	O	O
G1	O	O
phase	O	O
.	O	O

Nevertheless	O	O
,	O	O
BARD1	O	O
polypeptides	O	O
are	O	O
found	O	O
exclusively	O	O
in	O	O
the	O	O
nuclear	O	O
fractions	O	O
of	O	O
both	O	O
G1	O	O
-	O	O
and	O	O
S	O	O
-	O	O
phase	O	O
cells	O	O
.	O	O

Therefore	O	O
,	O	O
progression	O	O
to	O	O
S	O	O
phase	O	O
is	O	O
accompanied	O	O
by	O	O
the	O	O
aggregation	O	O
of	O	O
nuclear	O	O
BARD1	O	O
polypeptides	O	O
into	O	O
BRCA1	O	O
nuclear	O	O
dots	O	O
.	O	O

Ventricular	B-Disease	D014693
fibrillation	I-Disease	D014693
causes	O	O
more	O	O
than	O	O
300	O	O
,	O	O
000	O	O
sudden	O	O
deaths	O	O
each	O	O
year	O	O
in	O	O
the	O	O
USA	O	O
alone	O	O
.	O	O

We	O	O
show	O	O
that	O	O
sodium	O	O
channels	O	O
with	O	O
the	O	O
missense	O	O
mutation	O	O
recover	O	O
from	O	O
inactivation	O	O
more	O	O
rapidly	O	O
than	O	O
normal	O	O
and	O	O
that	O	O
the	O	O
frameshift	O	O
mutation	O	O
causes	O	O
the	O	O
sodium	O	O
channel	O	O
to	O	O
be	O	O
non	O	O
-	O	O
functional	O	O
.	O	O

.	O	O

BACKGROUND	O	O
&	O	O
AIMS	O	O
Israeli	O	O
Jews	O	O
of	O	O
European	O	O
birth	O	O
,	O	O
i	O	O
.	O	O

e	O	O
.	O	O

0	O	O
%	O	O
of	O	O
120	O	O
European	O	O
and	O	O
1	O	O
.	O	O

6	O	O
%	O	O
of	O	O
188	O	O
non	O	O
-	O	O
European	O	O
Jews	O	O
(	O	O
P	O	O
=	O	O
0	O	O
.	O	O

08	O	O
)	O	O
.	O	O

It	O	O
occurred	O	O
in	O	O
15	O	O
.	O	O

Clinical	O	O
and	O	O
radiographic	O	O
examinations	O	O
were	O	O
performed	O	O
to	O	O
establish	O	O
diagnoses	O	O
,	O	O
and	O	O
disease	O	O
severity	O	O
was	O	O
assessed	O	O
using	O	O
a	O	O
combination	O	O
of	O	O
validated	O	O
scoring	O	O
systems	O	O
.	O	O

HLA	O	O
typing	O	O
for	O	O
HLA	O	O
-	O	O
B27	O	O
,	O	O
HLA	O	O
-	O	O
B60	O	O
,	O	O
and	O	O
HLA	O	O
-	O	O
DR1	O	O
was	O	O
performed	O	O
by	O	O
polymerase	O	O
chain	O	O
reaction	O	O
with	O	O
sequence	O	O
-	O	O
specific	O	O
primers	O	O
,	O	O
and	O	O
zygosity	O	O
was	O	O
assessed	O	O
using	O	O
microsatellite	O	O
markers	O	O
.	O	O

RESULTS	O	O
Six	O	O
of	O	O
8	O	O
monozygotic	O	O
(	O	O
MZ	O	O
)	O	O
twin	O	O
pairs	O	O
were	O	O
disease	O	O
concordant	O	O
,	O	O
compared	O	O
with	O	O
4	O	O
of	O	O
15	O	O
B27	O	O
-	O	O
positive	O	O
dizygotic	O	O
(	O	O
DZ	O	O
)	O	O
twin	O	O
pairs	O	O
(	O	O
27	O	O
%	O	O
)	O	O
and	O	O
4	O	O
of	O	O
32	O	O
DZ	O	O
twin	O	O
pairs	O	O
overall	O	O
(	O	O
12	O	O
.	O	O

5	O	O
%	O	O
)	O	O
.	O	O

Nonsignificant	O	O
increases	O	O
in	O	O
similarity	O	O
with	O	O
regard	O	O
to	O	O
age	O	O
at	O	O
disease	O	O
onset	O	O
and	O	O
all	O	O
of	O	O
the	O	O
disease	O	O
severity	O	O
scores	O	O
assessed	O	O
were	O	O
noted	O	O
in	O	O
disease	O	O
-	O	O
concordant	O	O
MZ	O	O
twins	O	O
compared	O	O
with	O	O
concordant	O	O
DZ	O	O
twins	O	O
.	O	O

HLA	O	O
-	O	O
B27	O	O
and	O	O
B60	O	O
were	O	O
associated	O	O
with	O	O
the	O	O
disease	O	O
in	O	O
probands	O	O
,	O	O
and	O	O
the	O	O
rate	O	O
of	O	O
disease	O	O
concordance	O	O
was	O	O
significantly	O	O
increased	O	O
among	O	O
DZ	O	O
twin	O	O
pairs	O	O
in	O	O
which	O	O
the	O	O
co	O	O
-	O	O
twin	O	O
was	O	O
positive	O	O
for	O	O
both	O	O
B27	O	O
and	O	O
DR1	O	O
.	O	O

Additive	O	O
genetic	O	O
effects	O	O
were	O	O
estimated	O	O
to	O	O
contribute	O	O
97	O	O
%	O	O
of	O	O
the	O	O
population	O	O
variance	O	O
.	O	O

The	O	O
I1307K	O	O
allele	O	O
was	O	O
found	O	O
in	O	O
6	O	O
.	O	O

2	O	O
)	O	O
.	O	O

The	O	O
gene	O	O
product	O	O
,	O	O
a	O	O
member	O	O
of	O	O
the	O	O
major	O	O
histocompatibility	O	O
complex	O	O
class	O	O
I	O	O
-	O	O
like	O	O
family	O	O
,	O	O
was	O	O
found	O	O
to	O	O
have	O	O
a	O	O
mutation	O	O
,	O	O
Cys	O	O
-	O	O
282	O	O
-	O	O
-	O	O
>	O	O
Tyr	O	O
(	O	O
C282Y	O	O
)	O	O
,	O	O
in	O	O
85	O	O
%	O	O
of	O	O
patient	O	O
chromosomes	O	O
.	O	O

This	O	O
mutation	O	O
eliminates	O	O
the	O	O
ability	O	O
of	O	O
HFE	O	O
to	O	O
associate	O	O
with	O	O
beta2	O	O
-	O	O
microglobulin	O	O
(	O	O
beta2m	O	O
)	O	O
and	O	O
prevents	O	O
cell	O	O
-	O	O
surface	O	O
expression	O	O
.	O	O

A	O	O
second	O	O
mutation	O	O
that	O	O
has	O	O
no	O	O
effect	O	O
on	O	O
beta2m	O	O
association	O	O
,	O	O
H63D	O	O
,	O	O
was	O	O
found	O	O
in	O	O
eight	O	O
out	O	O
of	O	O
nine	O	O
patients	O	O
heterozygous	O	O
for	O	O
the	O	O
C282Y	O	O
mutant	O	O
.	O	O

In	O	O
this	O	O
report	O	O
,	O	O
we	O	O
demonstrate	O	O
in	O	O
cultured	O	O
293	O	O
cells	O	O
overexpressing	O	O
wild	O	O
-	O	O
type	O	O
or	O	O
mutant	O	O
HFE	O	O
proteins	O	O
that	O	O
both	O	O
the	O	O
wild	O	O
-	O	O
type	O	O
and	O	O
H63D	O	O
HFE	O	O
proteins	O	O
form	O	O
stable	O	O
complexes	O	O
with	O	O
the	O	O
transferrin	O	O
receptor	O	O
(	O	O
TfR	O	O
)	O	O
.	O	O

The	O	O
C282Y	O	O
mutation	O	O
nearly	O	O
completely	O	O
prevents	O	O
the	O	O
association	O	O
of	O	O
the	O	O
mutant	O	O
HFE	O	O
protein	O	O
with	O	O
the	O	O
TfR	O	O
.	O	O

Studies	O	O
on	O	O
cell	O	O
-	O	O
associated	O	O
transferrin	O	O
at	O	O
37	O	O
degrees	O	O
C	O	O
suggest	O	O
that	O	O
the	O	O
overexpressed	O	O
wild	O	O
-	O	O
type	O	O
HFE	O	O
protein	O	O
decreases	O	O
the	O	O
affinity	O	O
of	O	O
the	O	O
TfR	O	O
for	O	O
transferrin	O	O
.	O	O

The	O	O
overexpressed	O	O
H63D	O	O
protein	O	O
does	O	O
not	O	O
have	O	O
this	O	O
effect	O	O
,	O	O
providing	O	O
the	O	O
first	O	O
direct	O	O
evidence	O	O
for	O	O
a	O	O
functional	O	O
consequence	O	O
of	O	O
the	O	O
H63D	O	O
mutation	O	O
.	O	O

Addition	O	O
of	O	O
soluble	O	O
wild	O	O
-	O	O
type	O	O
HFE	O	O
/	O	O
beta2m	O	O
heterodimers	O	O
to	O	O
cultured	O	O
cells	O	O
also	O	O
decreased	O	O
the	O	O
apparent	O	O
affinity	O	O
of	O	O
the	O	O
TfR	O	O
for	O	O
its	O	O
ligand	O	O
under	O	O
steady	O	O
-	O	O
state	O	O
conditions	O	O
,	O	O
both	O	O
in	O	O
293	O	O
cells	O	O
and	O	O
in	O	O
HeLa	O	O
cells	O	O
.	O	O

Furthermore	O	O
,	O	O
at	O	O
4	O	O
degrees	O	O
C	O	O
,	O	O
the	O	O
added	O	O
soluble	O	O
complex	O	O
of	O	O
HFE	O	O
/	O	O
beta2m	O	O
inhibited	O	O
binding	O	O
of	O	O
transferrin	O	O
to	O	O
HeLa	O	O
cell	O	O
TfR	O	O
in	O	O
a	O	O
concentration	O	O
-	O	O
dependent	O	O
manner	O	O
.	O	O

Scatchard	O	O
plots	O	O
of	O	O
these	O	O
data	O	O
indicate	O	O
that	O	O
the	O	O
added	O	O
heterodimer	O	O
substantially	O	O
reduced	O	O
the	O	O
affinity	O	O
of	O	O
TfR	O	O
for	O	O
transferrin	O	O
.	O	O

.	O	O

Cycloheximide	O	O
facilitates	O	O
the	O	O
identification	O	O
of	O	O
aberrant	O	O
transcripts	O	O
resulting	O	O
from	O	O
a	O	O
novel	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
in	O	O
COL17A1	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
generalized	O	O
atrophic	B-Disease	D016109
benign	I-Disease	D016109
epidermolysis	I-Disease	D016109
bullosa	I-Disease	D016109
.	O	O

Patients	O	O
with	O	O
generalized	O	O
atrophic	B-Disease	D016109
benign	I-Disease	D016109
epidermolysis	I-Disease	D016109
bullosa	I-Disease	D016109
often	O	O
show	O	O
decreased	O	O
expression	O	O
of	O	O
type	O	O
XVII	O	O
collagen	O	O
,	O	O
a	O	O
transmembrane	O	O
hemidesmosomal	O	O
protein	O	O
encoded	O	O
by	O	O
COL17A1	O	O
.	O	O

This	O	O
report	O	O
documents	O	O
a	O	O
novel	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
in	O	O
COL17A1	O	O
in	O	O
a	O	O
patient	O	O
with	O	O
generalized	O	O
atrophic	B-Disease	D016109
benign	I-Disease	D016109
epidermolysis	I-Disease	D016109
bullosa	I-Disease	D016109
,	O	O
and	O	O
applies	O	O
a	O	O
new	O	O
methodology	O	O
to	O	O
define	O	O
and	O	O
characterize	O	O
the	O	O
resulting	O	O
mRNA	O	O
splice	O	O
variants	O	O
.	O	O

Mutational	O	O
analysis	O	O
of	O	O
COL17A1	O	O
identified	O	O
a	O	O
maternally	O	O
inherited	O	O
G	O	O
-	O	O
to	O	O
-	O	O
T	O	O
transversion	O	O
at	O	O
the	O	O
-	O	O
1	O	O
position	O	O
of	O	O
exon	O	O
32	O	O
.	O	O

This	O	O
acceptor	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
led	O	O
to	O	O
the	O	O
formation	O	O
of	O	O
aberrant	O	O
transcripts	O	O
present	O	O
at	O	O
extremely	O	O
low	O	O
levels	O	O
.	O	O

Based	O	O
on	O	O
our	O	O
recent	O	O
finding	O	O
that	O	O
cycloheximide	O	O
stabilized	O	O
mutant	O	O
COL17A1	O	O
transcripts	O	O
in	O	O
keratinocytes	O	O
homozygous	O	O
for	O	O
a	O	O
frameshift	O	O
mutation	O	O
,	O	O
the	O	O
effects	O	O
of	O	O
the	O	O
splice	O	O
-	O	O
site	O	O
mutation	O	O
on	O	O
splicing	O	O
of	O	O
COL17A1	O	O
transcripts	O	O
were	O	O
determined	O	O
using	O	O
reverse	O	O
transcriptase	O	O
polymerase	O	O
chain	O	O
reaction	O	O
of	O	O
total	O	O
RNA	O	O
from	O	O
keratinocytes	O	O
incubated	O	O
for	O	O
2	O	O
.	O	O

5	O	O
h	O	O
in	O	O
the	O	O
presence	O	O
or	O	O
absence	O	O
of	O	O
10	O	O
microg	O	O
cycloheximide	O	O
per	O	O
ml	O	O
.	O	O

Using	O	O
this	O	O
approach	O	O
,	O	O
an	O	O
abnormally	O	O
spliced	O	O
transcript	O	O
was	O	O
identified	O	O
that	O	O
contains	O	O
an	O	O
extra	O	O
264	O	O
bases	O	O
upstream	O	O
from	O	O
exon	O	O
32	O	O
,	O	O
resulting	O	O
in	O	O
a	O	O
premature	O	O
termination	O	O
codon	O	O
27	O	O
bp	O	O
downstream	O	O
from	O	O
the	O	O
cryptic	O	O
splice	O	O
site	O	O
.	O	O

Three	O	O
other	O	O
splice	O	O
variants	O	O
,	O	O
including	O	O
one	O	O
derived	O	O
from	O	O
the	O	O
skipping	O	O
of	O	O
exon	O	O
32	O	O
,	O	O
were	O	O
also	O	O
identified	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
the	O	O
usefulness	O	O
of	O	O
cycloheximide	O	O
treatment	O	O
in	O	O
evaluating	O	O
the	O	O
abnormal	O	O
processing	O	O
of	O	O
mRNA	O	O
due	O	O
to	O	O
splice	O	O
-	O	O
site	O	O
mutations	O	O
,	O	O
because	O	O
(	O	O
i	O	O
)	O	O
aberrant	O	O
splicing	O	O
often	O	O
generates	O	O
a	O	O
premature	O	O
termination	O	O
codon	O	O
,	O	O
(	O	O
ii	O	O
)	O	O
transcripts	O	O
with	O	O
premature	O	O
termination	O	O
codons	O	O
can	O	O
occur	O	O
at	O	O
low	O	O
or	O	O
undetectable	O	O
levels	O	O
due	O	O
to	O	O
nonsense	O	O
-	O	O
mediated	O	O
mRNA	O	O
decay	O	O
,	O	O
and	O	O
(	O	O
iii	O	O
)	O	O
the	O	O
levels	O	O
of	O	O
these	O	O
transcripts	O	O
can	O	O
be	O	O
increased	O	O
by	O	O
cycloheximide	O	O
.	O	O

The	O	O
gene	O	O
segment	O	O
analyzed	O	O
corresponds	O	O
to	O	O
the	O	O
genomic	O	O
SacI	O	O
-	O	O
HindIII	O	O
fragment	O	O
carrying	O	O
exons	O	O
11	O	O
-	O	O
15	O	O
.	O	O

There	O	O
is	O	O
constitutive	O	O
methylation	O	O
in	O	O
intron	O	O
12	O	O
at	O	O
restriction	O	O
sites	O	O
of	O	O
SacII	O	O
and	O	O
HhaI	O	O
,	O	O
localized	O	O
1	O	O
,	O	O
159	O	O
-	O	O
1	O	O
,	O	O
232	O	O
bp	O	O
upstream	O	O
of	O	O
the	O	O
CTG	O	O
repeat	O	O
,	O	O
whereas	O	O
most	O	O
,	O	O
if	O	O
not	O	O
all	O	O
,	O	O
of	O	O
the	O	O
other	O	O
sites	O	O
of	O	O
SacII	O	O
,	O	O
HhaI	O	O
,	O	O
and	O	O
HpaII	O	O
in	O	O
this	O	O
region	O	O
are	O	O
unmethylated	O	O
,	O	O
in	O	O
normal	O	O
individuals	O	O
and	O	O
most	O	O
of	O	O
the	O	O
patients	O	O
.	O	O

In	O	O
a	O	O
number	O	O
of	O	O
young	O	O
and	O	O
severely	O	O
affected	O	O
patients	O	O
,	O	O
however	O	O
,	O	O
complete	O	O
methylation	O	O
of	O	O
these	O	O
restriction	O	O
sites	O	O
was	O	O
found	O	O
in	O	O
the	O	O
mutated	O	O
allele	O	O
.	O	O

In	O	O
most	O	O
of	O	O
these	O	O
patients	O	O
,	O	O
the	O	O
onset	O	O
of	O	O
the	O	O
disease	O	O
was	O	O
congenital	O	O
.	O	O

Preliminary	O	O
in	O	O
vivo	O	O
footprinting	O	O
data	O	O
gave	O	O
evidence	O	O
for	O	O
protein	O	O
-	O	O
DNA	O	O
contact	O	O
in	O	O
normal	O	O
genes	O	O
at	O	O
an	O	O
Sp1	O	O
consensus	O	O
binding	O	O
site	O	O
upstream	O	O
of	O	O
the	O	O
CTG	O	O
repeat	O	O
and	O	O
for	O	O
a	O	O
significant	O	O
reduction	O	O
of	O	O
this	O	O
interaction	O	O
in	O	O
cells	O	O
with	O	O
a	O	O
hypermethylated	O	O
DMPK	O	O
gene	O	O
.	O	O

.	O	O

This	O	O
instability	O	O
appears	O	O
to	O	O
be	O	O
biased	O	O
towards	O	O
further	O	O
expansion	O	O
and	O	O
continuous	O	O
throughout	O	O
the	O	O
life	O	O
of	O	O
an	O	O
individual	O	O
,	O	O
features	O	O
that	O	O
could	O	O
be	O	O
associated	O	O
with	O	O
the	O	O
progressive	O	O
nature	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

Although	O	O
increasing	O	O
measured	O	O
allele	O	O
size	O	O
between	O	O
patients	O	O
clearly	O	O
correlates	O	O
with	O	O
an	O	O
increased	O	O
severity	O	O
of	O	O
symptoms	O	O
and	O	O
an	O	O
earlier	O	O
age	O	O
of	O	O
onset	O	O
,	O	O
this	O	O
correlation	O	O
is	O	O
not	O	O
precise	O	O
and	O	O
measured	O	O
allele	O	O
length	O	O
cannot	O	O
be	O	O
used	O	O
as	O	O
an	O	O
accurate	O	O
predictor	O	O
of	O	O
age	O	O
of	O	O
onset	O	O
.	O	O

We	O	O
have	O	O
found	O	O
a	O	O
direct	O	O
progression	O	O
of	O	O
the	O	O
size	O	O
heterogeneity	O	O
over	O	O
time	O	O
related	O	O
to	O	O
initial	O	O
CTG	O	O
repeat	O	O
size	O	O
and	O	O
the	O	O
time	O	O
interval	O	O
and	O	O
always	O	O
biased	O	O
towards	O	O
further	O	O
expansion	O	O
.	O	O

Attempts	O	O
to	O	O
mathematically	O	O
model	O	O
the	O	O
dynamics	O	O
have	O	O
proved	O	O
only	O	O
partially	O	O
successful	O	O
suggesting	O	O
that	O	O
individual	O	O
specific	O	O
genetic	O	O
and	O	O
/	O	O
or	O	O
environmental	O	O
factors	O	O
also	O	O
play	O	O
a	O	O
role	O	O
in	O	O
somatic	O	O
mosaicism	O	O
.	O	O

.	O	O

1	O	O
%	O	O
)	O	O
of	O	O
476	O	O
patients	O	O
.	O	O

5	O	O
-	O	O
1	O	O
.	O	O

01	O	O
)	O	O
.	O	O

03	O	O
)	O	O
,	O	O
as	O	O
well	O	O
as	O	O
a	O	O
younger	O	O
age	O	O
at	O	O
diagnosis	O	O
.	O	O

The	O	O
disease	O	O
susceptibility	O	O
of	O	O
individuals	O	O
who	O	O
constitutionally	O	O
lack	O	O
both	O	O
wild	O	O
-	O	O
type	O	O
alleles	O	O
is	O	O
unknown	O	O
.	O	O

DNA	O	O
sequence	O	O
analysis	O	O
and	O	O
allele	O	O
-	O	O
specific	O	O
amplification	O	O
in	O	O
two	O	O
siblings	O	O
revealed	O	O
a	O	O
homozygous	O	O
MLH1	O	O
mutation	O	O
(	O	O
C676T	O	O
-	O	O
-	O	O
>	O	O
Arg226Stop	O	O
)	O	O
.	O	O

.	O	O

Qualitative	O	O
analysis	O	O
of	O	O
the	O	O
Dp71	O	O
transcript	O	O
and	O	O
testing	O	O
for	O	O
the	O	O
specific	O	O
first	O	O
exon	O	O
of	O	O
Dp140	O	O
were	O	O
also	O	O
carried	O	O
out	O	O
.	O	O

Neuropsychological	O	O
analysis	O	O
assessed	O	O
verbal	O	O
and	O	O
visuospatial	O	O
intelligence	O	O
,	O	O
verbal	O	O
memory	O	O
,	O	O
and	O	O
reading	O	O
skills	O	O
.	O	O

.	O	O

We	O	O
have	O	O
found	O	O
strong	O	O
evidence	O	O
for	O	O
a	O	O
locus	O	O
on	O	O
chromosome	O	O
4p	O	O
at	O	O
D4S2949	O	O
(	O	O
maximum	O	O
GENEHUNTER	O	O
-	O	O
PLUS	O	O
nonparametric	O	O
linkage	O	O
score	O	O
=	O	O
4	O	O
.	O	O

05	O	O
,	O	O
P	O	O
=	O	O
5	O	O
.	O	O

22	O	O
x	O	O
10	O	O
(	O	O
-	O	O
4	O	O
)	O	O
;	O	O
SIBPAL	O	O
Pempirical	O	O
value	O	O
<	O	O
3	O	O
x	O	O
10	O	O
(	O	O
-	O	O
5	O	O
)	O	O
)	O	O
and	O	O
suggestive	O	O
evidence	O	O
for	O	O
a	O	O
locus	O	O
on	O	O
chromosome	O	O
4q	O	O
at	O	O
D4S397	O	O
(	O	O
maximum	O	O
GENEHUNTER	O	O
-	O	O
PLUS	O	O
nonparametric	O	O
linkage	O	O
score	O	O
=	O	O
3	O	O
.	O	O

29	O	O
,	O	O
P	O	O
=	O	O
2	O	O
.	O	O

57	O	O
x	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
;	O	O
SIBPAL	O	O
Pempirical	O	O
value	O	O
<	O	O
1	O	O
x	O	O
10	O	O
(	O	O
-	O	O
3	O	O
)	O	O
)	O	O
that	O	O
are	O	O
linked	O	O
to	O	O
mental	O	O
health	O	O
wellness	O	O
.	O	O

I	O	O
.	O	O

Clinical	O	O
,	O	O
immunochemical	O	O
,	O	O
and	O	O
family	O	O
studies	O	O
.	O	O

C5	O	O
was	O	O
undetectable	O	O
in	O	O
her	O	O
serum	O	O
by	O	O
both	O	O
immunodiffusion	O	O
and	O	O
hemolytic	O	O
assays	O	O
.	O	O

Other	O	O
complement	O	O
components	O	O
were	O	O
normal	O	O
during	O	O
remission	O	O
of	O	O
lupus	O	O
,	O	O
but	O	O
C1	O	O
,	O	O
C4	O	O
,	O	O
C2	O	O
,	O	O
and	O	O
C3	O	O
levels	O	O
fell	O	O
during	O	O
exacerbations	O	O
.	O	O

A	O	O
younger	O	O
half	O	O
-	O	O
sister	O	O
,	O	O
who	O	O
had	O	O
no	O	O
underlying	O	O
disease	O	O
,	O	O
was	O	O
also	O	O
found	O	O
to	O	O
lack	O	O
immunochemically	O	O
detectable	O	O
C5	O	O
.	O	O

By	O	O
hemolytic	O	O
assay	O	O
,	O	O
she	O	O
exhibited	O	O
1	O	O
-	O	O
2	O	O
%	O	O
of	O	O
the	O	O
normal	O	O
serum	O	O
C5	O	O
level	O	O
and	O	O
normal	O	O
concentrations	O	O
of	O	O
other	O	O
complement	O	O
components	O	O
.	O	O

.	O	O

.	O	O

We	O	O
have	O	O
sequenced	O	O
the	O	O
expressed	O	O
exons	O	O
of	O	O
the	O	O
C6	O	O
gene	O	O
from	O	O
selected	O	O
cases	O	O
and	O	O
have	O	O
found	O	O
three	O	O
molecular	O	O
defects	O	O
leading	O	O
to	O	O
total	O	O
deficiency	O	O
879delG	O	O
,	O	O
which	O	O
is	O	O
the	O	O
common	O	O
defect	O	O
in	O	O
the	O	O
Cape	O	O
and	O	O
hitherto	O	O
unreported	O	O
,	O	O
and	O	O
1195delC	O	O
and	O	O
1936delG	O	O
,	O	O
which	O	O
have	O	O
been	O	O
previously	O	O
reported	O	O
in	O	O
African	O	O
-	O	O
Americans	O	O
.	O	O

We	O	O
also	O	O
show	O	O
that	O	O
the	O	O
879delG	O	O
and	O	O
1195delC	O	O
defects	O	O
are	O	O
associated	O	O
with	O	O
characteristic	O	O
C6	O	O
/	O	O
C7	O	O
region	O	O
DNA	O	O
marker	O	O
haplotypes	O	O
,	O	O
although	O	O
small	O	O
variations	O	O
were	O	O
observed	O	O
.	O	O

The	O	O
1936delG	O	O
defect	O	O
was	O	O
observed	O	O
only	O	O
once	O	O
in	O	O
the	O	O
Cape	O	O
,	O	O
but	O	O
its	O	O
associated	O	O
haplotype	O	O
could	O	O
be	O	O
deduced	O	O
.	O	O

The	O	O
data	O	O
from	O	O
the	O	O
haplotypes	O	O
indicate	O	O
that	O	O
these	O	O
three	O	O
molecular	O	O
defects	O	O
account	O	O
for	O	O
the	O	O
defects	O	O
in	O	O
all	O	O
the	O	O
38	O	O
unrelated	O	O
C6Q0	O	O
individuals	O	O
we	O	O
have	O	O
studied	O	O
from	O	O
the	O	O
Cape	O	O
.	O	O

.	O	O

,	O	O
1997	O	O
)	O	O
.	O	O

We	O	O
have	O	O
investigated	O	O
the	O	O
R496H	O	O
mutation	O	O
and	O	O
found	O	O
this	O	O
mutation	O	O
at	O	O
a	O	O
relatively	O	O
high	O	O
frequency	O	O
in	O	O
an	O	O
African	O	O
American	O	O
population	O	O
(	O	O
f	O	O
=	O	O
0	O	O
.	O	O

09	O	O
,	O	O
n	O	O
=	O	O
61	O	O
subjects	O	O
)	O	O
.	O	O

The	O	O
ARSA	O	O
enzyme	O	O
activity	O	O
in	O	O
subjects	O	O
with	O	O
and	O	O
without	O	O
the	O	O
R496H	O	O
mutation	O	O
was	O	O
determined	O	O
and	O	O
found	O	O
to	O	O
be	O	O
normal	O	O
.	O	O

.	O	O

Overall	O	O
,	O	O
disease	O	O
was	O	O
linked	O	O
to	O	O
BRCA1	O	O
in	O	O
an	O	O
estimated	O	O
52	O	O
%	O	O
of	O	O
families	O	O
,	O	O
to	O	O
BRCA2	O	O
in	O	O
32	O	O
%	O	O
of	O	O
families	O	O
,	O	O
and	O	O
to	O	O
neither	O	O
gene	O	O
in	O	O
16	O	O
%	O	O
(	O	O
95	O	O
%	O	O
confidence	O	O
interval	O	O
[	O	O
CI	O	O
]	O	O
6	O	O
%	O	O
-	O	O
28	O	O
%	O	O
)	O	O
,	O	O
suggesting	O	O
other	O	O
predisposition	O	O
genes	O	O
.	O	O

These	O	O
estimates	O	O
were	O	O
not	O	O
substantially	O	O
affected	O	O
either	O	O
by	O	O
changing	O	O
the	O	O
assumed	O	O
penetrance	O	O
model	O	O
for	O	O
BRCA1	O	O
or	O	O
by	O	O
including	O	O
or	O	O
excluding	O	O
BRCA1	O	O
mutation	O	O
data	O	O
.	O	O

Among	O	O
those	O	O
families	O	O
with	O	O
disease	O	O
due	O	O
to	O	O
BRCA1	O	O
that	O	O
were	O	O
tested	O	O
by	O	O
one	O	O
of	O	O
the	O	O
standard	O	O
screening	O	O
methods	O	O
,	O	O
mutations	O	O
were	O	O
detected	O	O
in	O	O
the	O	O
coding	O	O
sequence	O	O
or	O	O
splice	O	O
sites	O	O
in	O	O
an	O	O
estimated	O	O
63	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
51	O	O
%	O	O
-	O	O
77	O	O
%	O	O
)	O	O
.	O	O

The	O	O
estimated	O	O
sensitivity	O	O
was	O	O
identical	O	O
for	O	O
direct	O	O
sequencing	O	O
and	O	O
other	O	O
techniques	O	O
.	O	O

The	O	O
penetrance	O	O
of	O	O
BRCA2	O	O
was	O	O
estimated	O	O
by	O	O
maximizing	O	O
the	O	O
LOD	O	O
score	O	O
in	O	O
BRCA2	O	O
-	O	O
mutation	O	O
families	O	O
,	O	O
over	O	O
all	O	O
possible	O	O
penetrance	O	O
functions	O	O
.	O	O

4	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
0	O	O
%	O	O
-	O	O
1	O	O
%	O	O
)	O	O
by	O	O
age	O	O
50	O	O
years	O	O
and	O	O
27	O	O
%	O	O
(	O	O
95	O	O
%	O	O
CI	O	O
0	O	O
%	O	O
-	O	O
47	O	O
%	O	O
)	O	O
by	O	O
age	O	O
70	O	O
years	O	O
.	O	O

Sequential	O	O
cleavage	O	O
of	O	O
the	O	O
precursor	O	O
protein	O	O
pre	O	O
-	O	O
pro	O	O
-	O	O
opiomelanocortin	O	O
(	O	O
POMC	O	O
)	O	O
generates	O	O
the	O	O
melanocortin	O	O
peptides	O	O
adrenocorticotrophin	O	O
(	O	O
ACTH	O	O
)	O	O
,	O	O
melanocyte	O	O
-	O	O
stimulating	O	O
hormones	O	O
(	O	O
MSH	O	O
)	O	O
alpha	O	O
,	O	O
beta	O	O
and	O	O
gamma	O	O
as	O	O
well	O	O
as	O	O
the	O	O
opioid	O	O
-	O	O
receptor	O	O
ligand	O	O
beta	O	O
-	O	O
endorphin	O	O
.	O	O

While	O	O
a	O	O
few	O	O
cases	O	O
of	O	O
isolated	O	O
ACTH	B-Disease	OMIM:201400
deficiency	I-Disease	OMIM:201400
have	O	O
been	O	O
reported	O	O
(	O	O
OMIM	O	O
201400	O	O
)	O	O
,	O	O
an	O	O
inherited	O	O
POMC	O	O
defect	O	O
has	O	O
not	O	O
been	O	O
described	O	O
so	O	O
far	O	O
.	O	O

The	O	O
observation	O	O
of	O	O
these	O	O
symptoms	O	O
in	O	O
two	O	O
probands	O	O
prompted	O	O
us	O	O
to	O	O
search	O	O
for	O	O
mutations	O	O
within	O	O
their	O	O
POMC	O	O
genes	O	O
.	O	O

Patient	O	O
1	O	O
was	O	O
found	O	O
to	O	O
be	O	O
a	O	O
compound	O	O
heterozygote	O	O
for	O	O
two	O	O
mutations	O	O
in	O	O
exon	O	O
3	O	O
(	O	O
G7013T	O	O
,	O	O
C7133delta	O	O
)	O	O
which	O	O
interfere	O	O
with	O	O
appropriate	O	O
synthesis	O	O
of	O	O
ACTH	O	O
and	O	O
alpha	O	O
-	O	O
MSH	O	O
.	O	O

Patient	O	O
2	O	O
was	O	O
homozygous	O	O
for	O	O
a	O	O
mutation	O	O
in	O	O
exon	O	O
2	O	O
(	O	O
C3804A	O	O
)	O	O
which	O	O
abolishes	O	O
POMC	O	O
translation	O	O
.	O	O

.	O	O

Homozygous	O	O
Smad4	O	O
mutant	O	O
mice	O	O
die	O	O
before	O	O
day	O	O
7	O	O
.	O	O

5	O	O
of	O	O
embryogenesis	O	O
.	O	O

Mutant	O	O
embryos	O	O
have	O	O
reduced	O	O
size	O	O
,	O	O
fail	O	O
to	O	O
gastrulate	O	O
or	O	O
express	O	O
a	O	O
mesodermal	O	O
marker	O	O
,	O	O
and	O	O
show	O	O
abnormal	O	O
visceral	O	O
endoderm	O	O
development	O	O
.	O	O

Rescued	O	O
embryos	O	O
show	O	O
severe	O	O
anterior	O	O
truncations	O	O
,	O	O
indicating	O	O
a	O	O
second	O	O
important	O	O
role	O	O
for	O	O
Smad4	O	O
in	O	O
anterior	O	O
patterning	O	O
during	O	O
embryogenesis	O	O
.	O	O

Mutation	O	O
screening	O	O
and	O	O
sequence	O	O
analysis	O	O
disclosed	O	O
the	O	O
involvement	O	O
of	O	O
three	O	O
different	O	O
ARSA	O	O
mutations	O	O
being	O	O
the	O	O
molecular	O	O
basis	O	O
of	O	O
intrafamilial	O	O
phenotypic	O	O
heterogeneity	O	O
.	O	O

The	O	O
late	O	O
infantile	O	O
patient	O	O
inherited	O	O
from	O	O
his	O	O
mother	O	O
the	O	O
frequent	O	O
0	O	O
-	O	O
type	O	O
mutation	O	O
459	O	O
+	O	O
1G	O	O
>	O	O
A	O	O
,	O	O
and	O	O
from	O	O
his	O	O
father	O	O
a	O	O
novel	O	O
,	O	O
single	O	O
basepair	O	O
microdeletion	O	O
of	O	O
guanine	O	O
at	O	O
nucleotide	O	O
7	O	O
in	O	O
exon	O	O
1	O	O
(	O	O
7delG	O	O
)	O	O
.	O	O

The	O	O
two	O	O
clinically	O	O
unaffected	O	O
siblings	O	O
carried	O	O
the	O	O
maternal	O	O
mutation	O	O
459	O	O
+	O	O
1G	O	O
>	O	O
A	O	O
and	O	O
,	O	O
on	O	O
their	O	O
paternal	O	O
allele	O	O
,	O	O
a	O	O
novel	O	O
cytosine	O	O
to	O	O
thymidine	O	O
transition	O	O
at	O	O
nucleotide	O	O
2435	O	O
in	O	O
exon	O	O
8	O	O
,	O	O
resulting	O	O
in	O	O
substitution	O	O
of	O	O
alanine	O	O
464	O	O
by	O	O
valine	O	O
(	O	O
A464V	O	O
)	O	O
.	O	O

The	O	O
fathers	O	O
genotype	O	O
thus	O	O
was	O	O
7delG	O	O
/	O	O
A464V	O	O
.	O	O

Moreover	O	O
,	O	O
further	O	O
ARSA	O	O
alleles	O	O
functionally	O	O
similar	O	O
to	O	O
A464V	O	O
might	O	O
exist	O	O
which	O	O
,	O	O
together	O	O
with	O	O
0	O	O
-	O	O
type	O	O
mutations	O	O
,	O	O
may	O	O
cause	O	O
pathological	O	O
ARSA	O	O
and	O	O
GS	O	O
levels	O	O
,	O	O
but	O	O
not	O	O
clinical	O	O
outbreak	O	O
of	O	O
the	O	O
disease	O	O
.	O	O

.	O	O

Low	O	O
levels	O	O
of	O	O
beta	O	O
hexosaminidase	O	O
A	O	O
in	O	O
healthy	O	O
individuals	O	O
with	O	O
apparent	O	O
deficiency	O	O
of	O	O
this	O	O
enzyme	O	O
.	O	O

Identification	O	O
and	O	O
quantitation	O	O
of	O	O
hex	O	O
A	O	O
,	O	O
amounting	O	O
to	O	O
3	O	O
.	O	O

5	O	O
%	O	O
-	O	O
6	O	O
.	O	O

9	O	O
%	O	O
of	O	O
total	O	O
beta	O	O
hexosaminidase	O	O
activity	O	O
,	O	O
has	O	O
been	O	O
obtained	O	O
by	O	O
cellulose	O	O
acetate	O	O
gel	O	O
electrophoresis	O	O
,	O	O
DEAE	O	O
-	O	O
cellulose	O	O
ion	O	O
-	O	O
exchange	O	O
chromatography	O	O
,	O	O
radial	O	O
immunodiffusion	O	O
,	O	O
and	O	O
radioimmunoassay	O	O
.	O	O

Thus	O	O
,	O	O
the	O	O
postulated	O	O
rate	O	O
mutant	O	O
gene	O	O
appears	O	O
to	O	O
code	O	O
for	O	O
the	O	O
expression	O	O
of	O	O
low	O	O
amounts	O	O
of	O	O
hex	O	O
A	O	O
.	O	O

Imprinting	O	O
in	O	O
the	O	O
15q11	O	O
-	O	O
q13	O	O
region	O	O
involves	O	O
an	O	O
imprinting	O	O
centre	O	O
(	O	O
IC	O	O
)	O	O
,	O	O
mapping	O	O
in	O	O
part	O	O
to	O	O
the	O	O
promoter	O	O
and	O	O
first	O	O
exon	O	O
of	O	O
SNRPN	O	O
.	O	O

These	O	O
data	O	O
demonstrate	O	O
that	O	O
both	O	O
the	O	O
position	O	O
of	O	O
the	O	O
IC	O	O
and	O	O
its	O	O
role	O	O
in	O	O
the	O	O
coordinate	O	O
expression	O	O
of	O	O
genes	O	O
is	O	O
conserved	O	O
between	O	O
mouse	O	O
and	O	O
human	O	O
,	O	O
and	O	O
indicate	O	O
that	O	O
the	O	O
mouse	O	O
is	O	O
a	O	O
suitable	O	O
model	O	O
system	O	O
in	O	O
which	O	O
to	O	O
investigate	O	O
the	O	O
molecular	O	O
mechanisms	O	O
of	O	O
imprinting	O	O
in	O	O
this	O	O
region	O	O
of	O	O
the	O	O
genome	O	O
.	O	O

.	O	O

A	O	O
deletion	O	O
mutation	O	O
in	O	O
COL17A1	O	O
in	O	O
five	O	O
Austrian	O	O
families	O	O
with	O	O
generalized	O	O
atrophic	B-Disease	D016109
benign	I-Disease	D016109
epidermolysis	I-Disease	D016109
bullosa	I-Disease	D016109
represents	O	O
propagation	O	O
of	O	O
an	O	O
ancestral	O	O
allele	O	O
.	O	O

Skin	B-Disease	C536183
fragility	I-Disease	C536183
in	O	O
most	O	O
cases	O	O
is	O	O
due	O	O
to	O	O
mutations	O	O
in	O	O
the	O	O
gene	O	O
encoding	O	O
type	O	O
XVII	O	O
collagen	O	O
(	O	O
COL17A1	O	O
)	O	O
.	O	O

Recently	O	O
,	O	O
we	O	O
reported	O	O
five	O	O
Austrian	O	O
families	O	O
with	O	O
generalized	O	O
atrophic	B-Disease	D016109
benign	I-Disease	D016109
epidermolysis	I-Disease	D016109
bullosa	I-Disease	D016109
who	O	O
share	O	O
the	O	O
same	O	O
COL17A1	O	O
mutation	O	O
.	O	O

Affected	O	O
individuals	O	O
in	O	O
three	O	O
families	O	O
are	O	O
homozygous	O	O
for	O	O
4003delTC	O	O
,	O	O
whereas	O	O
those	O	O
in	O	O
two	O	O
others	O	O
are	O	O
compound	O	O
heterozygotes	O	O
.	O	O

To	O	O
determine	O	O
if	O	O
the	O	O
occurrence	O	O
of	O	O
4003delTC	O	O
in	O	O
these	O	O
unrelated	O	O
families	O	O
signifies	O	O
propagation	O	O
of	O	O
an	O	O
ancestral	O	O
allele	O	O
or	O	O
a	O	O
mutational	O	O
hot	O	O
spot	O	O
,	O	O
haplotypes	O	O
were	O	O
determined	O	O
for	O	O
polymorphisms	O	O
both	O	O
within	O	O
and	O	O
flanking	O	O
COL17A1	O	O
.	O	O

Five	O	O
intragenic	O	O
polymorphisms	O	O
were	O	O
chosen	O	O
based	O	O
on	O	O
their	O	O
informativeness	O	O
.	O	O

One	O	O
of	O	O
these	O	O
,	O	O
not	O	O
previously	O	O
reported	O	O
,	O	O
was	O	O
2988	O	O
A	O	O
or	O	O
C	O	O
that	O	O
introduces	O	O
a	O	O
new	O	O
restriction	O	O
site	O	O
for	O	O
Eco0109	O	O
I	O	O
.	O	O

All	O	O
the	O	O
4003delTC	O	O
alleles	O	O
showed	O	O
the	O	O
same	O	O
haplotype	O	O
for	O	O
these	O	O
five	O	O
polymorphic	O	O
markers	O	O
.	O	O

Fourteen	O	O
microsatellite	O	O
polymorphisms	O	O
were	O	O
selected	O	O
based	O	O
on	O	O
their	O	O
high	O	O
heterozygosity	O	O
and	O	O
their	O	O
location	O	O
within	O	O
10q23	O	O
-	O	O
q25	O	O
near	O	O
COL17A1	O	O
.	O	O

Three	O	O
families	O	O
shared	O	O
microsatellite	O	O
polymorphisms	O	O
covering	O	O
at	O	O
most	O	O
19	O	O
cM	O	O
,	O	O
whereas	O	O
the	O	O
others	O	O
shared	O	O
smaller	O	O
regions	O	O
consistent	O	O
with	O	O
cross	O	O
-	O	O
over	O	O
events	O	O
during	O	O
passage	O	O
of	O	O
this	O	O
mutation	O	O
through	O	O
several	O	O
generations	O	O
.	O	O

These	O	O
results	O	O
indicate	O	O
that	O	O
4003delTC	O	O
occurs	O	O
on	O	O
a	O	O
single	O	O
ancestral	O	O
allele	O	O
.	O	O

.	O	O

Identification	O	O
of	O	O
a	O	O
novel	O	O
mutation	O	O
of	O	O
the	O	O
CPO	O	O
gene	O	O
in	O	O
a	O	O
Japanese	O	O
hereditary	B-Disease	D046349
coproporphyria	I-Disease	D046349
family	O	O
.	O	O

Only	O	O
11	O	O
mutations	O	O
of	O	O
the	O	O
gene	O	O
have	O	O
been	O	O
reported	O	O
in	O	O
HCP	B-Disease	D046349
patients	O	O
.	O	O

We	O	O
report	O	O
another	O	O
mutation	O	O
in	O	O
a	O	O
Japanese	O	O
family	O	O
.	O	O

Polymerase	O	O
chain	O	O
reaction	O	O
-	O	O
single	O	O
strand	O	O
conformational	O	O
polymorphism	O	O
and	O	O
direct	O	O
sequence	O	O
analyses	O	O
demonstrated	O	O
a	O	O
C	O	O
to	O	O
T	O	O
substitution	O	O
in	O	O
exon	O	O
1	O	O
of	O	O
the	O	O
CPO	O	O
gene	O	O
at	O	O
nucleotide	O	O
position	O	O
85	O	O
,	O	O
which	O	O
lies	O	O
in	O	O
the	O	O
putative	O	O
presequence	O	O
for	O	O
targeting	O	O
to	O	O
mitochondria	O	O
.	O	O

This	O	O
mutation	O	O
changes	O	O
the	O	O
codon	O	O
for	O	O
glutamine	O	O
to	O	O
a	O	O
termination	O	O
codon	O	O
at	O	O
amino	O	O
acid	O	O
position	O	O
29	O	O
.	O	O

MaeI	O	O
restriction	O	O
analysis	O	O
showed	O	O
two	O	O
other	O	O
carriers	O	O
in	O	O
the	O	O
family	O	O
.	O	O

The	O	O
C	O	O
-	O	O
T	O	O
mutation	O	O
is	O	O
located	O	O
within	O	O
a	O	O
recently	O	O
proposed	O	O
putative	O	O
alternative	O	O
translation	O	O
initiation	O	O
codon	O	O
(	O	O
TIC	O	O
-	O	O
1	O	O
)	O	O
,	O	O
supporting	O	O
that	O	O
TIC	O	O
-	O	O
1	O	O
is	O	O
the	O	O
real	O	O
TIC	O	O
rather	O	O
than	O	O
TIC	O	O
-	O	O
2	O	O
.	O	O

.	O	O

035	O	O
.	O	O

04	O	O
.	O	O

18	O	O
families	O	O
with	O	O
21	O	O
informative	O	O
matings	O	O
for	O	O
both	O	O
properdin	O	O
Factor	O	O
B	O	O
allotype	O	O
and	O	O
HLA	O	O
-	O	O
B	O	O
were	O	O
found	O	O
.	O	O

Of	O	O
72	O	O
informative	O	O
meioses	O	O
,	O	O
three	O	O
recombinants	O	O
were	O	O
found	O	O
,	O	O
giving	O	O
a	O	O
recombinant	O	O
fraction	O	O
of	O	O
0	O	O
.	O	O

042	O	O
.	O	O

A	O	O
lod	O	O
score	O	O
of	O	O
16	O	O
between	O	O
HLA	O	O
-	O	O
B	O	O
and	O	O
Factor	O	O
B	O	O
allotypes	O	O
was	O	O
calculated	O	O
at	O	O
a	O	O
maximum	O	O
likelihood	O	O
value	O	O
of	O	O
the	O	O
recombinant	O	O
fraction	O	O
of	O	O
0	O	O
.	O	O

04	O	O
.	O	O

A	O	O
crossover	O	O
was	O	O
shown	O	O
to	O	O
have	O	O
occurred	O	O
between	O	O
genes	O	O
for	O	O
Factor	O	O
B	O	O
and	O	O
HLA	O	O
-	O	O
D	O	O
,	O	O
in	O	O
which	O	O
HLA	O	O
-	O	O
D	O	O
segregared	O	O
with	O	O
HLA	O	O
-	O	O
A	O	O
and	O	O
B	O	O
.	O	O

A	O	O
single	O	O
band	O	O
shift	O	O
using	O	O
SSCP	O	O
was	O	O
identified	O	O
in	O	O
exon	O	O
21	O	O
which	O	O
resulted	O	O
in	O	O
a	O	O
missense	O	O
mutation	O	O
converting	O	O
a	O	O
cys	O	O
-	O	O
-	O	O
>	O	O
arg	O	O
at	O	O
nucleotide	O	O
position	O	O
28	O	O
in	O	O
the	O	O
exon	O	O
.	O	O

The	O	O
mutation	O	O
destroyed	O	O
an	O	O
NdeI	O	O
restriction	O	O
enzyme	O	O
site	O	O
.	O	O

These	O	O
observations	O	O
point	O	O
to	O	O
another	O	O
region	O	O
of	O	O
the	O	O
RB1	O	O
gene	O	O
where	O	O
mutations	O	O
only	O	O
modify	O	O
the	O	O
function	O	O
of	O	O
the	O	O
gene	O	O
and	O	O
raise	O	O
important	O	O
questions	O	O
for	O	O
genetic	O	O
counseling	O	O
in	O	O
families	O	O
with	O	O
these	O	O
distinctive	O	O
phenotypes	O	O
.	O	O

.	O	O

All	O	O
these	O	O
new	O	O
molecular	O	O
defects	O	O
involve	O	O
single	O	O
-	O	O
nucleotide	O	O
events	O	O
,	O	O
deletions	O	O
and	O	O
substitutions	O	O
,	O	O
some	O	O
of	O	O
which	O	O
alter	O	O
splice	O	O
sites	O	O
,	O	O
and	O	O
others	O	O
codons	O	O
.	O	O

They	O	O
are	O	O
distributed	O	O
along	O	O
the	O	O
C7	O	O
gene	O	O
,	O	O
but	O	O
predominantly	O	O
towards	O	O
the	O	O
3	O	O
end	O	O
.	O	O

All	O	O
were	O	O
found	O	O
in	O	O
compound	O	O
heterozygous	O	O
individuals	O	O
.	O	O

.	O	O

We	O	O
analyzed	O	O
genotype	O	O
/	O	O
phenotype	O	O
correlations	O	O
,	O	O
on	O	O
the	O	O
basis	O	O
of	O	O
the	O	O
constitution	O	O
of	O	O
a	O	O
WT1	O	O
mutation	O	O
database	O	O
of	O	O
84	O	O
germ	O	O
-	O	O
line	O	O
mutations	O	O
,	O	O
to	O	O
compare	O	O
the	O	O
distribution	O	O
and	O	O
type	O	O
of	O	O
mutations	O	O
,	O	O
according	O	O
to	O	O
the	O	O
different	O	O
symptoms	O	O
.	O	O

.	O	O

He	O	O
presented	O	O
with	O	O
respiratory	O	O
and	O	O
feeding	O	O
difficulties	O	O
at	O	O
birth	O	O
.	O	O

.	O	O

Genomic	O	O
organization	O	O
of	O	O
the	O	O
UBE3A	O	O
/	O	O
E6	O	O
-	O	O
AP	O	O
gene	O	O
and	O	O
related	O	O
pseudogenes	O	O
.	O	O

Previous	O	O
UBE3A	O	O
cDNA	O	O
analysis	O	O
has	O	O
shown	O	O
a	O	O
coding	O	O
region	O	O
of	O	O
approximately	O	O
2	O	O
.	O	O

6	O	O
kb	O	O
and	O	O
a	O	O
3	O	O
-	O	O
untranslated	O	O
region	O	O
(	O	O
UTR	O	O
)	O	O
of	O	O
<	O	O
50	O	O
bp	O	O
,	O	O
whereas	O	O
Northern	O	O
analysis	O	O
has	O	O
indicated	O	O
mRNA	O	O
sizes	O	O
of	O	O
5	O	O
-	O	O
8	O	O
kb	O	O
.	O	O

We	O	O
have	O	O
analyzed	O	O
additional	O	O
cDNA	O	O
clones	O	O
and	O	O
provide	O	O
evidence	O	O
for	O	O
an	O	O
additional	O	O
0	O	O
.	O	O

5	O	O
kb	O	O
of	O	O
5	O	O
-	O	O
UTR	O	O
and	O	O
>	O	O
2	O	O
kb	O	O
of	O	O
3	O	O
-	O	O
UTR	O	O
.	O	O

We	O	O
have	O	O
established	O	O
the	O	O
genomic	O	O
organization	O	O
of	O	O
UBE3A	O	O
and	O	O
the	O	O
sequence	O	O
of	O	O
intron	O	O
-	O	O
exon	O	O
borders	O	O
.	O	O

We	O	O
have	O	O
also	O	O
mapped	O	O
two	O	O
highly	O	O
homologous	O	O
processed	O	O
pseudogenes	O	O
,	O	O
UBE3AP1	O	O
and	O	O
UBE3AP2	O	O
,	O	O
to	O	O
chromosomes	O	O
2	O	O
and	O	O
21	O	O
,	O	O
respectively	O	O
,	O	O
and	O	O
determined	O	O
their	O	O
genomic	O	O
organization	O	O
.	O	O

These	O	O
results	O	O
will	O	O
form	O	O
the	O	O
basis	O	O
for	O	O
studies	O	O
of	O	O
mutation	O	O
and	O	O
imprinting	O	O
of	O	O
UBE3A	O	O
.	O	O

It	O	O
is	O	O
one	O	O
member	O	O
of	O	O
a	O	O
family	O	O
of	O	O
lamina	O	O
-	O	O
associated	O	O
proteins	O	O
which	O	O
includes	O	O
LAP1	O	O
,	O	O
LAP2	O	O
and	O	O
lamin	O	O
B	O	O
receptor	O	O
(	O	O
LBR	O	O
)	O	O
.	O	O

A	O	O
panel	O	O
of	O	O
16	O	O
monoclonal	O	O
antibodies	O	O
(	O	O
mAbs	O	O
)	O	O
has	O	O
been	O	O
mapped	O	O
to	O	O
six	O	O
specific	O	O
sites	O	O
throughout	O	O
the	O	O
emerin	O	O
molecule	O	O
using	O	O
phage	O	O
-	O	O
displayed	O	O
peptide	O	O
libraries	O	O
and	O	O
has	O	O
been	O	O
used	O	O
to	O	O
localize	O	O
emerin	O	O
in	O	O
human	O	O
and	O	O
rabbit	O	O
heart	O	O
.	O	O

Several	O	O
mAbs	O	O
against	O	O
different	O	O
emerin	O	O
epitopes	O	O
did	O	O
not	O	O
recognize	O	O
intercalated	O	O
discs	O	O
in	O	O
the	O	O
heart	O	O
,	O	O
though	O	O
they	O	O
recognized	O	O
cardiomyocyte	O	O
nuclei	O	O
strongly	O	O
,	O	O
both	O	O
at	O	O
the	O	O
rim	O	O
and	O	O
in	O	O
intranuclear	O	O
spots	O	O
or	O	O
channels	O	O
.	O	O

A	O	O
polyclonal	O	O
rabbit	O	O
antiserum	O	O
against	O	O
emerin	O	O
did	O	O
recognize	O	O
both	O	O
nuclear	O	O
membrane	O	O
and	O	O
intercalated	O	O
discs	O	O
but	O	O
,	O	O
after	O	O
affinity	O	O
purification	O	O
against	O	O
a	O	O
pure	O	O
-	O	O
emerin	O	O
band	O	O
on	O	O
a	O	O
western	O	O
blot	O	O
,	O	O
it	O	O
stained	O	O
only	O	O
the	O	O
nuclear	O	O
membrane	O	O
.	O	O

Although	O	O
emerin	O	O
was	O	O
abundant	O	O
in	O	O
the	O	O
membranes	O	O
of	O	O
cardiomyocyte	O	O
nuclei	O	O
,	O	O
it	O	O
was	O	O
absent	O	O
from	O	O
many	O	O
non	O	O
-	O	O
myocyte	O	O
cells	O	O
in	O	O
the	O	O
heart	O	O
.	O	O

In	O	O
contrast	O	O
,	O	O
lamin	O	O
B1	O	O
was	O	O
absent	O	O
from	O	O
cardiomyocyte	O	O
nuclei	O	O
,	O	O
showing	O	O
that	O	O
lamin	O	O
B1	O	O
is	O	O
not	O	O
essential	O	O
for	O	O
localization	O	O
of	O	O
emerin	O	O
to	O	O
the	O	O
nuclear	O	O
lamina	O	O
.	O	O

Lamin	O	O
B1	O	O
is	O	O
also	O	O
almost	O	O
completely	O	O
absent	O	O
from	O	O
skeletal	O	O
muscle	O	O
nuclei	O	O
.	O	O

.	O	O

